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ABSTRACT OF DISSERTATION 
 
 
 
 
COGNITIVE THERAPY FOR THE TREATMENT OF DEPRESSIVE SYMPTOMS 
IN PATIENTS WITH HEART FAILURE 
 
Depressive symptoms are common in patients with heart failure (HF) and 
adversely affect mortality, morbidity, and health-related quality of life. Cognitive therapy 
(CT) has been proposed as a non-pharmacological treatment for depressive symptoms 
in patients with HF. However, there is currently little evidence to support use of CT in 
patients with HF.  
 
The purpose of this dissertation was to develop and test a brief, nurse-delivered 
CT intervention for the treatment of depressive symptoms in patients with HF. Prior to 
testing the intervention, preliminary work was conducted resulting in four manuscripts: 1) 
a review of the evidence for CT in treating depressive symptoms in patients with 
cardiovascular conditions, 2) a description of living with depressive symptoms in patients 
with HF and strategies that could be used to manage these symptoms, 3) a review of 
measures of negative thinking and the identification of a measure of negative thinking 
that can be used in patients with HF, and 4) an evaluation of the psychometric properties 
of this measure. Based on information from these manuscripts, a randomized, controlled 
pilot study was conducted to test the effects of a brief CT intervention on outcomes of 
hospitalized patients with HF who report depressive symptoms. 
 
 Forty-two hospitalized patients with HF with mild-moderate depressive 
symptoms were randomized to a brief CT intervention focused on reducing negative 
thoughts with thought-stopping and affirmations, or to usual care control. Both groups 
experienced improvements in depressive symptoms, health-related quality of life, and 
negative thinking at one week and three months. However, the intervention group 
experienced longer cardiac event-free survival and fewer cardiovascular hospitalizations 
and emergency department visits at three months when compared to the control group.  
 
This dissertation has fulfilled an important gap in the evidence base for 
depression treatment in patients with HF by demonstrating that a nurse-delivered, brief 
CT intervention may improve cardiac event-free survival in patients with HF. This brief 
CT intervention is replicable, practical, can be delivered by acute care nurses, and may 
improve clinical outcomes in patients with HF. Additional research is needed to 
determine the effects of the intervention on long-term outcomes in patients with HF
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CHAPTER ONE: 
Introduction 
1. Depression in patients with heart failure 
 Heart failure (HF) is a chronic syndrome which affects 5.8 million people in the 
United States (U.S.).1 Age-adjusted five-year survival rates for individuals with HF have 
improved from 43% in 1979-1984 to 52% in 1996-2000.2 Unfortunately, despite 
improved survival, patients with HF continue to experience high morbidity in the form of 
frequent hospitalizations. The diagnosis of HF is the most common reason for 
hospitalization among elderly adults in the U.S.,3 and HF currently accounts for 1.08 
million hospital discharges per year—a 171% increase since 1979.
  In addition to high morbidity rates, patients with HF frequently experience major 
depressive disorder and depressive symptoms. In a meta-analysis of data from 23 
studies with over 10,000 participants with HF, researchers estimated that the prevalence 
of major depressive disorder, as determined by a diagnostic clinical interview, was 20% 
in outpatients and inpatients with HF. When researchers used a more liberal estimate 
(self-reported depression questionnaire), the prevalence rate of depressive symptoms 
was 30%.
1 
 Both major depressive disorder and self-reported depressive symptoms have 
significant clinical consequences in patients with HF. Patients with HF who have 
depressive symptoms are twice as likely to die and two and a half times more likely to be 
re-hospitalized than patients who do not have depressive symptoms.
4 
4 Researchers have 
also demonstrated a dose-response relationship between depressive symptoms and 
long-term survival in patients with HF. Patients with mild, moderate, and severe 
depressive symptoms as measured by the Beck Depression Inventory are respectively, 
21%, 53%, and 83% more likely to die during a seven-year follow-up period than 
patients who have no depressive symptoms.
 The reasons for the association between depressive symptoms and shortened 
survival in patients with HF are unclear. Depression and HF are two conditions that 
share important pathophysiological and behavioral links. Researchers have suggested 
that depression in patients with HF may be associated with proinflammatory cytokines, 
arrhythmias, sympathetic nervous system activation, and increased platelet aggregation, 
all of which may worsen the course of HF. Furthermore, depression may contribute to 
poor outcomes in HF via behavioral links such as non-adherence and poor social 
support.
5 
6 
 2 
 Researchers have found that the presence of depressive symptoms is an 
independent predictor of worsened health-related quality of life (HRQOL) in patients with 
HF.7, 8 HRQOL is a subjective, patient-centered outcome that refers to how a health 
condition affects a person’s total well-being. Researchers are beginning to recognize 
that HRQOL may be more important than quantity of life,9
 The problems associated with depressive symptoms in patients with HF have 
been well-described. However, there is a lack of research testing interventions for 
depressive symptoms in patients with HF.
 given that patients with HF are 
experiencing longer survival and must adjust to life with a chronic health condition. 
10
2. Treatment of depressive symptoms in patients with heart failure 
 Given the significant clinical consequences 
of depressive symptoms in patients with HF, it is imperative that researchers develop 
and test interventions for the treatment of depressive symptoms in patients with HF.  
 The 2009 guidelines for HF management from the American College of 
Cardiology and the American Heart Association provide no direction for the treatment of 
depression in patients with HF. The guidelines state, “Good evidence exists for the 
critical importance of delivering comprehensive supportive care to these patients, 
including the assessment and treatment of… depression.”11
 In the general population, evidence suggests that current pharmacological 
treatments for depression are only modestly effective compared to placebo. In 2008, 
Kirsch et al.
 The lack of specificity in 
these guidelines reflects the state of the science regarding the treatment of depression 
in patients with HF, as there has been insufficient research on treatments for depressive 
symptoms in patients with HF.  
12 
 Likewise, in the only randomized, controlled trial to date to test the effects of 
antidepressant therapy on depression in patients with HF (SADHART-HF), O’Connor et 
conducted a meta-analysis examining antidepressant efficacy using 
clinical trial data submitted to the Federal Food and Drug Administration and obtained 
with the Open Records Act. The authors found that among patients with moderate 
depression, there was a statistically significant difference between antidepressant and 
placebo use, but this difference did not meet criteria for clinical significance. Both drug 
and placebo resulted in modest improvements in depression. Among patients with the 
most severe levels of depression, antidepressant use resulted in a statistically and 
clinically significant improvement in depression compared to placebo. However, the 
researchers proposed that this improvement could have been due to a reduced placebo 
effect among the severely depressed, rather than an antidepressant effect. 
 3 
al.13
 The results of the SADHART-HF trial
 found that depressed patients with HF who received antidepressants did not 
experience a statistically significant improvement compared to placebo. However, both 
the intervention group and the placebo group received a nursing intervention as a part of 
the study protocol, and both groups experienced considerable reductions in depressive 
symptoms. The nursing intervention consisted of one-hour telephone counseling 
sessions that took place every other week for sixteen weeks and were delivered by a 
psychiatric nurse (Personal communication, C. O’Connor, March 3, 2010). The authors 
suggest that the nursing intervention was so powerful that the effects of the nursing 
intervention obscured any effect of the antidepressant.  
13
 Cognitive Therapy (CT) is a non-pharmacological intervention for depression that 
was developed by Beck in 1967,
 suggest that non-pharmacological 
interventions carried out by nurses may be effective for the treatment of depressive 
symptoms in patients with HF. Non-pharmacological interventions have several 
advantages over pharmacological treatments such as a lack of drug-drug interactions, 
immediate short-term relief of symptoms, and greater involvement of patients in their 
own self-care.  
14 has been used successfully to treat depression in 
multiple populations,15 and may be useful for treating depression in patients with HF. 
Nurses can be trained to administer CT as a nursing intervention. Cognitive Therapy is 
compatible with common nursing interventions such as teaching patients to accurately 
appraise stressors, determining the best coping method, and increasing perceived 
control.16
 Beck’s cognitive model of depression provides the theoretical basis for CT. The 
main tenet of the cognitive model is that negative thinking influences the emotional, 
behavioral, and somatic symptoms associated with depression.
  
17 Negative thinking can 
be defined as cognitions about the self, world, future, and interpersonal relationships.18 
Negative thinking originates in childhood and dominates the perceptions of the 
depressed individual.19 Examples of negative thoughts include, “I’m worthless,” 
“Everything I do is a failure,” and “Nothing’s ever going to work out for me.”18 Negative 
thinking occurs automatically and persists over time. Although the content of negative 
thoughts is irrational, these thoughts are believable to the person experiencing them.
 The goal of CT is to reduce depressive symptoms by redirecting negative 
thinking. During CT, the therapist teaches the client to identify, analyze, and question 
negative thoughts. For example, the therapist helps the client identify negative thoughts 
14 
 4 
such as “I’m a burden to my family.” Together, the therapist and the client explore the 
evidence for the negative thought. After evaluating the thought, the therapist guides the 
client to challenge the thought. By challenging and changing thoughts, the client is able 
to modify negative emotions and behaviors.17
Therefore, the purpose of this dissertation was to develop and test a CT 
intervention for managing depressive symptoms in patients with HF. The chapters of this 
dissertation represent the systematic development of my initial program of research.  
First, a review of the literature was performed to establish the evidence for CT as a 
treatment for depressive symptoms in patients with HF. Second, a qualitative research 
study was conducted that identified negative thinking as an important target for a CT-
based intervention that would be appropriate for patients with HF. Third, a critical review 
of the literature was conducted to identify the best instrument for measuring negative 
thinking in patients with HF. Fourth, evidence was provided for the reliability and validity 
of the selected measure of negative thinking in patients with HF. And finally, a clinically 
feasible, brief CT intervention for depressive symptoms targeting negative thinking in 
patients with HF was tested in a randomized clinical trial.  
 Although CT holds promise as a potential 
treatment for depressive symptoms in patients with HF, research is needed to 
demonstrate its efficacy as a treatment for depressive symptoms in patients with HF. 
3. Summary of subsequent chapters  
 Chapter Two is the critical review of the literature20
  Chapter Three is the qualitative research study
 to determine the empirical 
support for the use of CT in patients with HF. Because there was limited research on CT 
in patients with HF, the review was expanded to include research studies CT across all 
cardiovascular-related conditions. Insights from these studies were interpreted with 
respect to applicability to patients with HF. Electronic databases were searched from 
1980 through 2009 using the following key words: depression, cognitive therapy, 
cardiovascular, diabetes, and stroke. Articles were included if they met the following 
criteria: randomized, controlled trial; cognitive therapy intervention; depression or 
depressive symptoms measured as an outcome; sample consisted of patients with 
cardiovascular disease, non-hemorrhagic stroke, or diabetes. Fourteen articles met the 
inclusion criteria and were extracted for review. Positive effects of CT on depression or 
depressive symptoms were reported in eight of the fourteen studies. Possible reasons 
for the mixed results, as well as recommendations for the design of future studies testing 
CT in patients with HF are provided. 
21 conducted to obtain information 
 5 
needed to guide the development of a CT intervention for depressive symptoms in 
patients with HF. The research questions in this qualitative descriptive study were: How 
do persons with HF describe their depressive symptoms? What strategies do they use to 
reduce depressive symptoms? The sample consisted of ten outpatients with chronic HF 
who had clinically significant depressive symptoms as measured by the Beck 
Depression Inventory version II or a history of depression. Data were collected via taped, 
individual, 30-60 minute interviews which took place in the participants’ homes. Content 
analysis was conducted using the qualitative software ATLAS ti (v5). The participants 
identified negative thoughts that exacerbated their depressed mood. The most frequently 
mentioned strategy that participants used to manage their depressive symptoms was 
positive thinking, which included the use of affirmations. The findings from this study 
were used to develop a brief CT intervention which will be presented in Chapter Six. 
 Chapter Four is the critical review and analysis22
 Chapter Five is the report on the psychometric properties of the Crandell 
Cognitions Inventory (CCI) in patients with HF, to establish reliability and validity of this 
measure of negative thinking in patients with HF. The purpose of this study was to 
evaluate the internal consistency reliability and construct validity of the CCI in patients 
with HF. Cross-sectional questionnaire data were collected from 179 outpatients with HF 
using the CCI, Beck Depression Inventory-II, and Brief Symptom Inventory- anxiety 
subscale. Reliability was assessed with Cronbach’s alpha; construct validity was 
evaluated with factor analysis and hypothesis testing. The findings provided evidence for 
the reliability and validity of the CCI for measuring negative thinking in patients with HF. 
 of three measures of negative 
thinking to identify the best instrument for measurement of negative thinking in patients 
with HF. Three of the most widely used instruments that measure negative thinking were 
selected for review: the Crandell Cognitions Inventory, Automatic Thoughts 
Questionnaire, and Cognitive Checklist- Depression. The three instruments were 
described and their strengths and weaknesses were systematically compared, with 
particular attention to strength of evidence for reliability and validity. The Crandell 
Cognitions Inventory was identified as the instrument that has the best potential for 
measuring negative thinking in patients with HF, and recommendations for future 
psychometric testing were provided.  
 Chapter Six presents the findings of the randomized, controlled pilot study testing 
a brief CT intervention in hospitalized patients with HF. Patients were eligible to 
participate if they were admitted to the hospital with a diagnosis of HF and were 
 6 
experiencing mild to moderate depressive symptoms as measured by the Beck 
Depression Inventory-II. A total of forty-two patients were randomized to the intervention 
and control groups. The intervention group received a single 30-minute brief CT 
intervention at the bedside and a one-week telephone booster, and the control group 
received usual care. Depressive symptoms, negative thinking, and HRQOL were 
measured at baseline, one week, and three months. Three-month cardiac event-free 
survival data were also collected by patient interview and hospital record review. The 
results showed that both groups experienced significant improvements in depressive 
symptoms, negative thinking, and HRQOL over time. However, the intervention group 
experienced longer cardiac event-free survival compared to the usual care group (80% 
alive without a cardiac event vs. 40%, p = .048).  
 Chapter Seven is an integrated discussion in which the prior chapters of this 
dissertation are synthesized to advance the state of the science of treatment of 
depressive symptoms in patients with HF and make recommendations for practice and 
future research.  
Copyright © Rebecca L. Dekker 2010 
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CHAPTER TWO: 
Cognitive Therapy for Depressive Symptoms in Patients with Heart Failure: 
A Critical Review  
1. Introduction 
 Depression is a significant problem in patients with heart failure (HF). One in five 
persons with HF has clinical depression,1 and up to 48% have clinically significant 
depressive symptoms.2 According to the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV-TR), a major depressive episode, sometimes referred 
to as clinical depression, consists of five or more symptoms which are present for most 
of the day, almost daily, for at least two weeks. One of these symptoms must be either 
depressed mood or loss of interest or pleasure in usual activities, and the symptoms 
must cause significant distress in social, occupational, or other areas of functioning 
(Table 2.1).3 However, patients can experience clinically significant depressive 
symptoms without the presence of major depressive disorder.4 Depressive symptoms 
may include depressed mood, irritability, guilt, hopelessness, low self-esteem, fatigue, 
sleep disturbances, appetite change, and inability to concentrate.
 The adverse effects of clinical depression and depressive symptoms on mortality 
and hospitalizations in patients with HF have been well documented.
5 
1, 2, 6-8 Results from 
a recent meta-analysis demonstrated that patients with HF who have depressive 
symptoms are more than twice as likely to die or experience a cardiac event compared 
to patients without depressive symptoms.1 Moreover, the presence of depressive 
symptoms has a negative impact on every dimension of health-related quality of life in 
patients with HF, including physical functioning, social functioning, and mental health.2
 The problems associated with depression and depressive symptoms in patients 
with HF are well described. It is time for researchers to test interventions. Importantly, 
there is a lack of research on non-pharmacological interventions for depressive 
symptoms in patients with HF.
  
9 Cognitive therapy (CT) has been used successfully to 
treat depression in multiple populations.10, 11
2. Background 
 Therefore, it may also be useful for treating 
depression in patients with cardiovascular illnesses, including HF. The purpose of this 
critical review was to examine the empirical support for the use of CT in treating 
depression and depressive symptoms in patients with cardiovascular-related illnesses.  
Beck, a psychiatrist, developed the Cognitive Model of depression in 1967 to 
explain the psychological processes that occur in depression. The underlying 
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assumption behind the Cognitive Model was that human minds are biased and cannot 
interpret stimuli objectively. This bias leads to cognitive errors, or dysfunctional 
thinking.10 The Cognitive Model holds that dysfunctional thinking influences the 
emotions, behaviors, and psychosomatic symptoms associated with depression. Thus, 
interventions aimed at changing dysfunctional thinking should improve the emotional, 
behavioral, and somatic symptoms of depression.
Cognitive therapy, also referred to as cognitive behavioral therapy, is the 
psychotherapeutic intervention based on the Cognitive Model of depression. The primary 
goal of CT is to alter emotions and behavior by redirecting negative cognitive processes. 
CT is typically a short term therapy that consists of 4 to 14 sessions, depending on the 
individual’s progress. The role of the therapist is to develop a collaborative, therapeutic 
relationship with the client and to teach the client to become his or her own therapist. 
The therapist teaches the client to identify, analyze, and question dysfunctional thinking. 
For example, the therapist may help the client to identify negative thoughts such as “I’m 
a burden to others.” Together, the therapist and the client explore the evidence behind 
this negative thought. After evaluating the rationale for the thought, the therapist then 
guides the client to challenge the thought, and eventually change the client’s thinking. By 
creating changes in thinking, the client may modify negative emotions and behaviors.
11 
CT offers several potential advantages for the treatment of depression and 
depressive symptoms in patients with HF. First, CT is a non-pharmacological 
intervention. Non-pharmacological interventions may have several advantages over 
pharmacological treatments such as a lack of drug-drug interactions, immediate short-
term relief of symptoms, and greater involvement of patients in their own self-care. 
Second, CT is an intervention that nurses can be trained to administer. CT is compatible 
with common nursing interventions of teaching patients to accurately appraise stressors, 
determining the best coping method, and increasing perceived control. Despite the 
potential benefits of CT, its effectiveness in patients with cardiovascular illness including 
HF remains unknown. The following review provides a critical analysis of the existing 
research on the effectiveness of CT for treating depression or depressive symptoms in 
patients with cardiovascular illnesses.  
11 
3. Methods 
 The databases searched for relevant literature were PUBMED, PsychInfo, 
CINAHL, and MEDLINE. Keywords included depress* and cognitive therapy (or 
cognitive behavioral therapy) and cardiovascular (or heart failure, chronic illness, 
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coronary artery disease, cardiac, stroke, or diabetes). The search was limited to English 
language papers published between 1980 and 2009.  
 Studies were included in the review if they met the following criteria: randomized, 
controlled trial; a cognitive therapy intervention; depression or depressive symptoms 
measured as an outcome; sample consisted of patients with cardiovascular disease, 
non-hemorrhagic stroke, or diabetes. Diabetes mellitus commonly coexists with HF12 
and is an important risk factor for the development of HF.13
4. Results 
 Thus samples that contained 
patients with diabetes were also included.  
 The search resulted in 335 articles of which the titles or abstracts were screened 
for inclusion criteria. Reference lists of relevant articles were screened for additional 
studies. A total of fourteen papers met the inclusion criteria and were extracted for 
review.  
4.1. Cardiovascular disease 
 Eight studies were identified in which the impact of CT on depression in patients 
with cardiovascular illness was evaluated (Table 2.2).  
 In the largest randomized controlled trial on CT in cardiovascular disease to date, 
the ENRICHD (Enhancing Recovery in Coronary Heart Disease) investigators14
The lack of impact on event-free survival may have been due to several factors. 
The ENRICHD investigators assumed that CT should begin as soon as possible (within 
28 days) after an MI. Thus, the study may have included patients in the control group 
who had transient rather than clinical depression and recovered without intervention. 
The investigators also assumed that the usual care group would not receive treatment 
for depression, but this was not the case. Antidepressant use was comparable in the 
 
compared the impact of CT with usual care on depressive symptoms and event-free 
survival in 2,481 patients with a recent myocardial infarction (MI). Patients were eligible 
to participate if they were defined as depressed on a diagnostic interview or if they had 
low perceived social support. Patients in the intervention group attended 6 to 19 
individual or group CT sessions (median of 11 sessions) over six months in conjunction 
with selective serotonin reuptake inhibitor when indicated. The intervention group 
experienced a statistically significant decrease in depressive symptoms compared to the 
control group at six months. However, this difference was no longer present at 30 or 42 
months of follow up. There was no difference in event-free survival between the 
intervention and control groups.  
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control group (21%) and intervention group (28%).14-16 It is not known why a decrease in 
depressive symptoms in the intervention group in this study did not translate into 
improved outcomes. It may be that the decrease in depressive symptoms was 
insufficient to affect clinical outcomes. This conclusion is supported by the observation 
that while depressive symptoms in the intervention group decreased by 49%, depressive 
symptoms in the control group also decreased by 33%.
 More recently, Freedland et al. 
14 
17
 The investigators found that patients in both intervention groups were more likely 
to experience remission from depression at all time points compared to patients in the 
usual care group. At nine months, 73% of the CT group and 57% of the stress 
management group experienced remission from depression, compared to 23% of 
patients in the usual care group (p = .003). This study was underpowered to detect 
differences between the CT and stress management arms of the study. Therefore, it is 
difficult to draw conclusions as to whether CT or stress management was superior for 
the treatment of depression in patients who are post-CABG. However, patients who 
received CT experienced greater improvement in secondary outcomes such as lower 
anxiety, hopelessness, and perceived stress; these results suggest that CT may offer 
more benefits to patients in comparison to stress management.  
 compared the effects of CT, supportive stress 
management, and usual care for the treatment of depression in 123 patients who were 
post coronary artery bypass graft surgery (CABG). Patients were included if they scored 
10 or higher on the Beck Depression Inventory (BDI) and met the DSM-IV criteria for 
depression based on a diagnostic interview. The investigators tested two separate 
interventions: 12 weeks of CT and 12 weeks of supportive stress management 
(progressive relaxation, controlled breathing, and imagery); both interventions were 
delivered in individual sessions by a trained clinical social worker or psychologist. 
Follow-up information on depression was collected at 3, 6, and 9 months using the BDI 
and the Hamilton Rating Scale for Depression.  
 Twenty years ago, Burgess et al.18 reported that an intervention combining CT, 
social support, and job return counseling failed to reduce depressive symptoms in 
patients who had recently experienced an acute MI. In this randomized, controlled trial, 
180 patients were randomized to the intervention group or usual care.  There were no 
differences in depression scores between groups at baseline, three months, or thirteen 
months of follow-up. The authors did not offer any explanations for the null effects on 
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depression. Females were underrepresented in the study; thus, it is not known whether 
the intervention would have been effective for females.  
 CT may be effective in reducing depressive symptoms in survivors of sudden 
cardiac death. Cowan et al19, 20
 Limited evidence suggests that CT may be more effective than exercise at 
reducing depressive symptoms in patients with coronary artery disease. Black et al
 tested the impact of CT, biofeedback therapy, and health 
education on depressive symptoms and mortality in 133 survivors of sudden cardiac 
death. Only 11% of the sample had depressive symptoms at baseline and all of these 
were male. Approximately half of the sample had chronic heart failure (NYHA Functional 
Class II-IV). The treatment group experienced a significant decrease in depressive 
symptoms compared to the control group. Although the study was not originally powered 
to detect differences in mortality, the treatment group experienced an 86% reduction in 
the risk of cardiac death compared to the control group. Therefore, the results of this 
study suggest that CT and biofeedback may be beneficial for survivors of sudden 
cardiac death, whether or not they are experiencing depressive symptoms.   
21
 Results from three studies suggest that CT may be helpful for reducing 
depressive symptoms in patients with implanted cardioverter defibrillators (ICDs). 
Frizelle et al.
 
randomized 60 patients who had recently been hospitalized for a coronary event and 
were psychologically distressed to one of two groups: a special intervention that 
consisted of stress management, relaxation training, and CT administered by a 
psychiatrist, or a cardiac rehabilitation group that included exercise and risk reduction 
counseling. At six months, the CT group experienced a significant reduction in 
depressive symptoms compared to the cardiac rehabilitation group. There was no 
difference between groups with regard to rehospitalizations. There were several 
limitations of the study such as low representation of women (12%), exclusion of elderly 
(>80 years old), and lack of a true control group. Most importantly, adherence to the 
intervention was low. Less than 50% of participants attended more than one intervention 
session. Crossover between groups was also a problem, as six participants in the usual 
care group were treated with antidepressants or psychological counseling. Combined, 
these limitations severely weakened the internal and external validity of the study. 
22 compared the impact of a cardiac rehabilitation and CT to a wait list 
control group on depressive symptoms in patients with ICDs. Despite the small sample 
size (N = 22), the intervention group experienced a significant reduction in depressive 
symptoms compared to the control group at three months. The intervention included 
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exercise, which makes it impossible to ascertain whether the CT alone had an impact on 
depressive symptoms.  
 In another study, Kohn et al.23
 Lewin et al.
 evaluated the effects of CT on depressive 
symptoms in 49 patients with ICDs. This study was limited by the lack of a 
comprehensive measure of depressive symptoms at baseline. Only three biological 
indicators of depression were measured at baseline: sexual functioning difficulties, 
changes in appetite, and sleep disturbance. At nine months follow-up, the CT group 
reported fewer sexual functioning difficulties than the control group; however, sexual 
difficulties increased in both groups over time. The BDI version II (BDI-II) was 
administered only at follow-up. Although the CT group had a lower BDI-II score than the 
control group at follow-up, the lack of depression score data at baseline limits the 
conclusions that can be drawn from findings.  
24
 In a logistic regression, the investigators found that patients in the intervention 
group were less likely to experience depression at six months compared to patients from 
control centers, after adjusting for baseline depression score (OR -0.46, Confidence 
interval -1.93 to 1.00). Furthermore, the intervention group had a greater reduction in the 
proportion of patients with depression at six months compared to the control group (-
13.2% vs. -2.1%, p value not specified). However, this study was limited by the lack of a 
thorough description of the CT intervention, which limits researchers’ ability to replicate 
the results and translate the study findings to the clinical setting. 
 tested the effects of a brief, self-help CT booklet for the treatment 
of depressive symptoms in patients who were undergoing ICD implantation. In this RCT, 
eight ICD implantation centers were randomized to intervention or control. The 
intervention consisted of several booklets that were given to the patient and family by 
healthcare providers who had received a half day of training in administering the 
intervention. One of the booklets consisted of a self-help cognitive behavioral 
rehabilitation program, but the intervention in this booklet was not described in further 
detail. Patients in the intervention arm also received three phone contacts after ICD 
implantation to discuss their progress and set goals. The authors defined depression as 
a HADS score of 8 or greater, and patients were followed for six months. 
 Finally, results from a small study suggest that an intense regimen of CT 
combined with exercise may reduce depressive symptoms in patients with heart failure 
(HF).25 In this study, 20 patients with HF (NYHA Class II/III) were randomized to three 
groups: group-based CT plus exercise, Digoxin titrated to achieve drug levels between 
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0.8 – 2.0 ng/mL, or placebo. Despite the small sample size, the intervention group 
experienced a 52% reduction in depressive symptoms while the other groups 
experienced a 15% and 25% increase in depressive symptoms, respectively. As a result 
of the combination of exercise with CT, it is not known whether CT alone would have 
been effective in decreasing depressive symptoms. In addition, the follow up period was 
short, only 12 weeks, and therefore no conclusions can be drawn regarding the long-
term effects of the intervention. 
4.2. Stroke  
 There is less evidence regarding the effectiveness of CT on depression in 
patients with stroke. Lincoln and Flannaghan26
 The authors suggested that the intervention, which consisted of ten one-hour 
sessions, may not have been intense enough to improve depressive symptoms more 
than would occur naturally. However, other investigators have tested CT in chronic 
illness and found positive results using a similar number of CT sessions.
 conducted a randomized, controlled trial 
in which 123 patients who had recently experienced a stroke and depressive symptoms 
(scored > 10 on the BDI) were assigned to one of three groups: CT, an attention placebo 
group, or a control group. Surprisingly, depressive symptoms improved over time in all of 
the groups. There were no significant differences between the groups at baseline, three 
months, and six months of follow up.  
14, 27 It is 
possible that the improvement in depressive symptoms in all three groups over time may 
have reflected the natural improvement of depression that occurs over time after an 
acute stroke.
4.3. Diabetes 
26 
 The effectiveness of CT for the management of depression in patients with 
diabetes has been tested in four randomized, controlled trials. Lustman et al.27
 In contrast, investigators from three studies have found that CT was not effective 
for treating depressive symptoms in adults with diabetes. Snoek et al.
 
conducted a RCT in which 51 patients with type 2 diabetes and clinical depression were 
assigned to either ten weeks of CT and diabetes education or an education-only group. 
As a result of the intervention, the treatment group had a higher rate of remission from 
depression compared to the control group (58.3% vs. 25.9%).  
28 compared the 
effects of two interventions on depressive symptoms in adults with type 2 diabetes. The 
two interventions that were compared were a six week group CT intervention and a 
blood glucose awareness training. The results showed no differences between groups at 
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6 and 12 months follow up. There was no true usual care group; by comparing two 
active interventions, the investigators may have been less likely to detect a difference in 
the improvement of depressive symptoms between groups.  
 Similarly, Henry et al.29
 In a much larger study of 344 adults with type 1 diabetes, Ismail et al.
 also found that CT did not improve depressive symptoms 
in patients with type 2 diabetes. The investigators in this small RCT used a wait list 
control to evaluate the effects of CT plus progressive muscle relaxation on depressive 
symptoms in nineteen patients with type 2 diabetes and elevated levels of glycosylated 
hemoglobin. Although there was an overall decrease in depressive symptoms from pre-
treatment to post-treatment in both the intervention and wait-list groups, there was no 
difference between groups. Because of the small sample size, the study likely was 
under-powered to detect changes in depressive symptoms between groups.  
30
5. Discussion  
 also 
found that CT did not improve depressive symptoms. In this RCT, the investigators 
compared CT plus motivational enhancement therapy and motivational enhancement 
therapy alone to usual care in the treatment of depressive symptoms. Despite the 
lengthy intervention (up to 12 sessions over 6 months), a large sample size, and a 
rigorous design, neither of the intervention groups experienced a greater reduction in 
depressive symptoms over time than the usual care group.  
5.1. Discussion of findings 
 Fourteen randomized, controlled trials were identified in which investigators 
tested the impact of CT on depression or depressive symptoms in patients with 
cardiovascular-related illnesses. Positive effects of CT on depression or depressive 
symptoms were reported in eight of the fourteen studies. This discussion section will 
report possible reasons for the mixed results, as well as limitations that prevent wide 
generalization of study findings.  
The major factors that contributed to the mixed results were that: 1) more than 
one intervention was tested in most studies, 2) there was a lack of a true, no-intervention 
control group in most studies, 3) most had small sample sizes, and 4) follow-up periods 
were short. The consequences of each of these factors are described below.  
 The presence of more than one treatment intervention in several studies 
restricted the ability to determine the effect of CT on outcomes. In two studies which 
found positive outcomes, CT and antidepressant therapy were combined,14, 21 making it 
impossible to determine the effect of CT alone on depressive symptoms. Similarly, in two 
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other studies finding positive outcomes, the intervention consisted of CT plus exercise.22, 
25 Although combined interventions may be a valuable addition to the treatment options 
for depressive symptoms in patients with cardiovascular disease, it is difficult to assess 
the value of CT by itself when it is tested in combination with other interventions. For 
example, a growing body of evidence has demonstrated that exercise is an effective 
treatment for persons with major depressive disorders or with depressive symptoms.31, 32
Six of the fourteen studies lacked a true, no-intervention group. These studies 
included a variety of comparison groups. For example, one group of investigators 
compared patients who received a CT intervention to patients who received a cardiac 
rehabilitation exercise intervention.
 
Thus exercise in combination with CT may have yielded a larger effect than CT alone or 
may obscure the effect of CT.  
21
Seven of the fourteen studies had small sample sizes (total N ranging from 19 to 
86), and eight studies had a follow-up period of six months or less. Interestingly, despite 
the ENRICHD trial’s large sample size and long follow up period (30 months), the 
investigators found only modest clinically significant reductions in depressive symptoms. 
Moreover, this benefit was no longer present by 30 months of follow-up, as all groups 
improved over time.
 Although these investigators found positive results 
with the CT intervention, the comparison of CT to exercise may have yielded a smaller 
effect than would have been seen if the investigators compared CT to a third, true 
control group. 
14
Researchers’ ability to generalize the findings of several of the reviewed studies 
is compromised by several factors: 1) vaguely described interventions, 2) 
underrepresentation of women, 3) use of a wide variety of instruments to measure 
depressive symptoms, and 4) failure to adhere to the CONSORT guidelines for the 
reporting of clinical trials.  
 In contrast, researchers of smaller studies found that CT reduced 
depressive symptoms at a relatively short follow-up time. It is possible that the 
improvements in depressive symptoms found in these studies did not persist. Short 
follow-up times limit the ability of researchers to determine whether CT is a potential 
long-term treatment for depression. 
First, researchers often included vague descriptions of the intervention in articles; 
this limits the ability of future researchers to replicate results from these studies as well 
as translate the findings to clinical practice. It is also possible that the investigators 
tested different forms of CT, which could contribute to the mixed findings.  
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 Second, only nine of the fourteen studies had samples that consisted of at least 
30% women. Of these nine studies, investigators in four studies found that CT reduced 
depressive symptoms. Previous researchers demonstrated that women may react 
differently to psychological interventions than men. In a post-hoc analysis, the ENRICHD 
investigators reported that white men who received the CT intervention had a reduced 
risk of experiencing cardiac mortality or recurrent MI. In contrast, there was no similar 
beneficial effect for women and minorities.33 Frasure-Smith et al.34
 Third, researchers used a variety of methods to measure clinical depression and 
depressive symptoms. Many of these measures, such as the Beck Depression 
Inventory, have established reliability and validity. In contrast, Kohn et al.
 reported that women 
who received an intense psychosocial nursing intervention after a myocardial infarction 
experienced an increase in all-cause mortality when compared to the control group 
(10.3% vs. 5.4%). This adverse effect was not found in the male participants. The results 
of these two studies suggest that it is important to evaluate the impact of psychological 
interventions on both men and women. Overall, the studies in this review provide 
insufficient evidence to determine the impact of CT on depressive symptoms in women 
with cardiovascular disease.  
23 used an 
instrument that measured three biological indicators of depression. The reliability and 
validity of this instrument was not provided. Overall, there was a lack of consistency on 
the measurement of depression in the reviewed studies. This limitation may restrict 
researchers from conducting future meta-analyses to examine the overall effect of CT for 
the treatment of depression in patients with cardiovascular disease. For this reason, in 
2006 a working group of the National Heart, Lung, and Blood Institute made 
recommendations as to which instruments researchers should use to measure 
depressive symptoms in clinical trials that include patients with cardiovascular disease.35
 Finally, of the twelve studies that were published after 1996, only five followed all 
of the CONSORT guidelines.
  
14, 26 The CONSORT (Consolidated Standards of Reporting 
Trials) guidelines were originally published in 1996 and have since been revised.36, 37 
These guidelines provide a standardized framework for the reporting of clinical trials. 
The CONSORT guidelines allow the reader to understand the design, conduct, analysis, 
and interpretation of a randomized controlled trial, and to judge whether a trial has 
internal or external validity.37 A lack of adherence to the CONSORT guidelines in several 
of the studies reduces the transparency of the reported clinical trials and could contribute 
to a bias in over-estimating the effects of interventions.  
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5.2. Implications for nursing research 
 The problems associated with depression and depressive symptoms in patients 
with HF have been adequately described. Interventions such as CT for the treatment of 
depression in patients with HF are now needed to move us forward. As only one small 
trial has studied the effects of CT in the treatment of depression in patients with HF, this 
article reviewed the empirical evidence for CT in the treatment of depression in patients 
with cardiovascular-related illnesses. Overall, the current evidence to support CT as a 
treatment for depression or depressive symptoms in patients with cardiovascular-related 
illnesses is inconclusive due to limitations of existing studies.  
 Based on this review, future clinical trials should include the following 
recommendations. Researchers should test the effect of a CT intervention alone as well 
as in combination with other treatments. The CT intervention should be replicable in a 
clinical setting. Careful consideration should be paid to the inclusion of an appropriate 
comparison group. Given that depression in patients with HF is associated with a high 
risk for morbidity and mortality, it may be unethical to withhold treatment for depression 
from patients who are severely depressed. Furthermore, CT alone may not be 
appropriate for severely depressed individuals. It is suggested that researchers should 
exclude patients with severe depression and instead refer them to their primary care 
providers for treatment.  
 Studies should be designed with sufficient sample sizes to be adequately 
powered to detect changes in depressive symptoms and related outcomes. Researchers 
should also make special efforts to include a representative sample of women. In 
addition, trials should include an adequate follow-up time of at least one year in order to 
provide information on the long-term effects of CT on both depression and other health 
outcomes, such as morbidity and mortality. It is also important that researchers use 
consistent methods for measuring depressive symptoms, such as issued in the National 
Heart, Lung, and Blood Institute’s recommendations.35 Finally, to improve transparency 
in the reporting of randomized, controlled trials, researchers should follow the 
CONSORT guidelines.37
 Several gaps in understanding of CT as a treatment for depression in 
cardiovascular conditions, including HF, remain. It is not known if there is a dose-
response relationship between CT and depression in patients with cardiovascular 
disease. For example, we do not know how many CT sessions are necessary to improve 
depression outcomes, or whether the effective dose varies among different 
.  
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cardiovascular populations. The best time to intervene for depressive symptoms in 
patients with cardiovascular disease is also unknown. The results of the ENRICHD trial 
showed that patients who had recently experienced a cardiac event and received a CT 
intervention only experienced a minimal improvement in depressive symptoms. This led 
researchers to question whether CT should be offered to patients who have recently 
experienced a cardiac event or if treatment should be delayed.15
5.3. Implications for nursing practice 
 Likewise, it is not 
known whether CT should be offered to patients with HF who have been recently 
hospitalized or whether their depression may remit on its own. Next, it is not known 
whether CT interventions should be offered only to patients with cardiovascular disease 
or HF who are clinically depressed or to all patients, regardless of depression status. 
Finally, it is unknown whether CT can affect outcomes related to depression such as 
mortality, morbidity, or health-related quality of life in patients with cardiovascular 
disease or HF.   
 Cognitive therapy is compatible with nursing practice and has been used 
successfully to treat depression in medically-healthy populations. Because there is a 
scarcity of evidence for patients with HF, this review was broadened to include all 
patients with cardiovascular-related illnesses. Based on the findings of this review, the 
current evidence is insufficient to recommend CT as a treatment for depressive 
symptoms in patients with cardiovascular illness. Although the majority of the studies 
reviewed demonstrated that CT may be effective, the limitations in study design prevent 
wide generalization of the results. More evidence is needed before it can be 
recommended that nurses routinely refer patients with cardiovascular disease to CT for 
the treatment of depression or depressive symptoms. It is important to also note that CT 
may not be appropriate for all patients with HF or cardiovascular disease, particularly for 
patients with cognitive impairment or those who may have difficulty adhering to the CT 
treatment protocol. These patients may benefit from alternative treatments for 
depression.  
6. Conclusion  
 Depression is a significant clinical problem in patients with HF. The time has 
come for researchers to focus their efforts on designing and testing non-pharmacological 
interventions for depression in patients with HF. Cognitive therapy holds promise as an 
intervention that may decrease depressive symptoms in patients with cardiovascular 
illness including HF. Nurses should continue to monitor the literature for new evidence 
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regarding the effectiveness of CT for treating depression in patients with HF and other 
cardiovascular disease. 
Copyright © Rebecca L. Dekker 2010  
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Table 2.1: DSM-IV-TR criteria for a major depressive episode 
At least 5 of the following symptoms have been present most of the day, nearly every 
day, during the same 2 week period and represent a change from previous 
functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of 
interest or pleasure:  
1. Depressed mood 
2. Loss of interest or pleasure 
3. Weight loss or changes in appetite 
4. Insomnia or hypersomnia 
5. Psychomotor agitation or retardation 
6. Fatigue 
7. Feelings of worthlessness or guilt 
8. Decreased ability to concentrate 
9. Thoughts of death, suicidal ideation, or suicide attempt.  
• The symptoms must cause significant impairment in functioning (i.e., work, social) 
• The symptoms must not be directly due to a medical condition (i.e., 
hypothyroidism) or a medication 
• The episode is not better accounted for by a different diagnosis such as 
bereavement, bipolar disorder, or schizoaffective disorder 
 
DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
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Table 2.2: Study characteristics and findings 
First 
author 
(year) 
Design, 
follow-up 
time 
Sample Measurement 
of depression 
Treatment  Control Results 
Cardiovascular Disease 
ENRICHD
(2003) 
14 RCT 
 
2 arms 
 
30 
months 
N = 2481 
 
28 days post-MI 
 
Eligible if 
classified as 
depressed or 
low perceived 
social support  
 
Females 44% 
Minorities 34% 
DISH, BDI, 
HRSD 
 
11 tailored CT 
sessions over 6 
months, group 
therapy as needed, 
referral to psychiatry 
for antidepressants 
as needed 
 
Usual care; 
physicians were 
notified if patients 
were depressed 
or had low 
perceived social 
support 
The CT group had a 
lower BDI score 
compared to control 
(9.1 vs. 12.2, p <.001), 
and a lower HRSD 
score (7.6 vs. 9.4, p 
<.001) at 6 months. 
This difference was not 
present at 30 or 42 
months 
Table 2.2: (Continued) 
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First 
author 
(year) 
Design, 
follow-up 
time 
Sample Measurement 
of depression 
Treatment  Control Results 
Freedland 
(2009)
RCT 
17  
3 arms 
 
9 months 
N = 123 
 
CABG surgery 
within the past 
year 
 
Eligible if 
scored ≥ 10 on 
the BDI and met 
DSM-IV criteria 
for major or 
minor 
depression 
based on the 
DISH 
 
Females 50% 
Minorities 19% 
 
HRSD score 
derived from 
the DISH; BDI 
1. CT: 12 weekly, 
individual, 50-60 
minute sessions with 
a therapist 
 
2. Supportive stress 
management: 12 
weekly, individual, 
50-60 minute 
session. Training 
included progressive 
relaxation, imagery, 
and controlled 
breathing 
Usual care  Patients in the CT and 
stress management 
group were more likely 
to experience 
remission from 
depression at 3, 6, and 
9 months compared to 
patients in the usual 
care group 
Burgess18 RCT  
(1987)  
2 arms 
 
13 
months 
N = 180 
 
Post acute MI 
 
Females 14% 
Minorities not 
reported 
ZDS A mean of 6.32 CT 
visits per patient, 
social support, 
facilitation of job 
return  
Usual care There were no 
differences between 
groups on depression 
scores at baseline or 
follow-up 
Table 2.2: (Continued) 
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First 
author 
(year) 
Design, 
follow-up 
time 
Sample Measurement 
of depression 
Treatment  Control Results 
Cowan19, 20 RCT   
(2001)  
2 arms 
 
3 months 
N = 133 
 
Sudden cardiac 
death survivors 
 
Females 27% 
Minorities 10% 
SCR-90: 
Depression 
subscale 
11 sessions of 
combined CT, 
biofeedback, and 
health education, 
administered 
biweekly for six 
weeks 
90 minute health 
education class 
Depressive symptoms 
decreased in the 
treatment group when 
compared to the 
control group 
Black21
(1998) 
  RCT 
 
2 arms 
 
6 months 
N = 60 
 
Recently 
hospitalized for 
angina, MI, 
angioplasty, or 
CABG 
 
Eligible if 
scored as 
distressed  
 
Females 12% 
Minorities not 
reported 
SCR-90: 
Depression 
subscale 
1 to 7 weekly 
sessions with a 
psychologist 
including: relaxation 
training, stress 
management, 
reduction of risk 
factors, efforts to 
improve adherence, 
and CT intervention; 
antidepressants if 
necessary 
Cardiac 
rehabilitation with 
monitored 
exercise 1-3 
times per week, 
for 8 weeks, daily 
home exercise. 
Education on 
stress 
management, 
support group 
meeting with 
spouses, 
individual nutrition 
counseling 
The CT group had 
significant reductions 
in depressive 
symptoms compared 
to the control group      
(-5.2 vs. -0.2, p < .034) 
 
Table 2.2: (Continued) 
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First 
author 
(year) 
Design, 
follow-up 
time 
Sample Measurement 
of depression 
Treatment  Control Results 
Frizelle22 RCT  
(2004)  
2 arms  
 
3 months 
 
 
N = 22 
 
Patients with 
ICD’s 
 
Females not 
reported 
Minorities not 
reported 
HADS Group-based 
therapy, six 
sessions, 1 hour 
each: home-based 
exercise, education, 
relaxation, behavioral 
goal setting, 
education on 
identifying and 
challenging negative 
thoughts  
Wait list   The treatment group 
experienced 
decreases in 
depressive symptoms 
compared to the 
control group 
(-4.25 vs. -0.2, p = 
.001) 
Kohn
(2000) 
23 RCT 
 
2 arms 
 
9 months 
N = 49  
 
Post-ICD 
implantation 
 
Females 35% 
African 
American 8% 
BDI version II;  
4 biological 
measures of 
depression: 
sexual 
functioning, 
appetite, 
weight 
change, and 
sleep patterns 
9 sessions ranging 
from 15-90 minutes, 
sessions included 
psycho-education on: 
anxieties about ICD, 
avoidance behavior, 
fear of shocks, stress 
management, work 
and social activities, 
distorted cognitions 
Usual care The CT group had 
lower levels of 
depressive symptoms 
at follow-up compared 
to the control group 
(6.9 vs. 15, p = .037), 
but depressive 
symptoms were not 
measured at baseline 
Table 2.2: (Continued) 
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First 
author 
(year) 
Design, 
follow-up 
time 
Sample Measurement 
of depression 
Treatment  Control Results 
Lewin24 Clustered 
RCT 
 
(2007) 
 
2 arms 
 
6 months 
N = 192 
 
Patients 
undergoing ICD 
implantation 
 
8 implantation 
centers in the 
UK were 
randomized to 
intervention or 
control 
 
Females 20% 
Minorities 3% 
HADS- 
Depression 
subscale 
Intervention 
consisted of 2 
booklets for patients, 
1 booklet for family, a 
goal-setting diary 
and a relaxation 
tape. The first 
booklet targeted 
fears prior to ICD 
implantation. The 
second booklet 
consisted of a self-
help CT program. 
The intervention was 
delivered by 
healthcare staff that 
underwent a half day 
of training.  
Usual care and 
contact by a 
study facilitator to 
discuss 
postoperative 
progress 
The intervention group 
experienced a greater 
reduction in the 
proportion of patients 
with depression at six 
months compared to 
the control group (-
13.2% vs. -2.1%, p 
value not reported) 
Table 2.2: (Continued) 
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First 
author 
(year) 
Design, 
follow-up 
time 
Sample Measurement 
of depression 
Treatment  Control Results 
Kostis25
(1994) 
  RCT 
 
3 arms 
 
3 months 
 
 
N = 20 
 
Patients with 
congestive 
heart failure  
 
Female 30% 
Minorities not 
reported 
BDI 12 weeks of exercise 
training at a cardiac 
rehab facility for 1 hr 
3 times per week; 
weekly meetings with 
a dietician; group-
based CT 
intervention: twice 
weekly for 60-90 
minutes (relaxation, 
positive imagery, 
appraisal of negative 
cognitions) 
 
 
 
1. Lanoxin titrated 
to achieve levels 
between 0.8-2.0 
ng/mL 
2. Placebo 
There was a 52% 
decrease in BDI 
scores in the 
intervention group 
compared to a 15% 
and 25% increase in 
the control groups at 
follow up (p = .04) 
Table 2.2: (Continued) 
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First 
author 
(year) 
Design, 
follow-up 
time 
Sample Measurement 
of depression 
Treatment  Control Results 
Stroke  
Lincoln
 (2003) 
26 RCT 
 
3 arms 
 
6 months 
N = 123 
 
1 to 6 months 
post-stroke 
 
Eligible if 
scored as 
depressed 
 
Female 49% 
Minorities not 
reported 
 
BDI 
WDI 
Ten 1-hour sessions 
over 3 months, 
tailored CT 
intervention: 
education, task 
assignment, activity 
scheduling, 
identification and 
modification of 
inaccurate thoughts 
1. No intervention  
2. Attention 
placebo: Ten 1 hr 
visits over 3 
months 
No significant 
differences between 
groups in depression 
scores 
 
Diabetes 
Lustman27 RCT  
(1998)  
2 arms 
 
6 months 
N = 51 
 
Type II diabetes 
and major 
depression  
 
Females 60% 
Minorities 19% 
DIS 
BDI 
 
1 hour per week of 
individual CT for 10 
weeks, strategies 
included: behavioral 
strategies, problem 
solving, and 
cognitive techniques 
to change cognitive 
errors 
Attention placebo: 
1 hour, biweekly, 
individual 
sessions with a 
diabetes educator 
The CT group had a 
higher rate of 
remission from 
depression compared 
to the control group 
(58.3% vs. 25.9%, p = 
.03) 
Table 2.2: (Continued) 
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First 
author 
(year) 
Design, 
follow-up 
time 
Sample Measurement 
of depression 
Treatment  Control Results 
Snoek28 RCT  
(2008)  
2 arms 
 
12 
months 
N = 86 
 
Adults with 
poorly 
controlled type I 
diabetes 
 
Females 58% 
Minorities: not 
reported 
CES-D 6 weekly group 
sessions of CT 
delivered by a 
diabetes nurse 
educator and a 
psychologist. 
Sessions focused on 
cognitive 
restructuring, 
behavior change and 
stress management  
Blood glucose 
awareness 
training focused 
on symptom 
management and 
diabetes 
education, 
delivered by a 
diabetes nurse 
educator and a 
psychologist 
There were no 
differences between 
groups with regard to 
change in depressive 
symptoms over time 
Henry29
(1997) 
  RCT 
 
2 arms 
 
7 weeks 
N = 19 
 
Type II 
Diabetes 
 
Females 53% 
Minorities not 
reported 
BDI Six sessions of 1.5 
hours: progressive 
muscle relaxation, 
cognitive coping 
training (such as 
identifying and 
modifying negative 
thoughts), problem-
solving skills, 
homework 
assignments 
Wait-list  Depressive symptoms 
decreased across time 
in both groups; there 
was no difference 
between groups 
Ismail30 RCT  
(2008)  
3 arms 
 
12 
months 
N = 344 
 
Adults with 
poorly 
controlled type I 
diabetes 
PHQ-9 1. CT plus 
motivational 
enhancement: 4 
individual sessions of 
motivational 
enhancement  
Usual care  Neither group 
experienced an 
improvement in 
depressive symptoms 
compared to usual 
care 
Table 2.2: (Continued) 
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First 
author 
(year) 
Design, 
follow-up 
time 
Sample Measurement 
of depression 
Treatment  Control Results 
 
Females 60% 
Minorities 20% 
 
therapy (see below) 
and 8 sessions of CT 
delivered over 6 
months by trained 
diabetes nurses  
2. Motivational 
enhancement: 4 
individual sessions 
delivered over 2 
months by a diabetes 
nurse. Sessions 
focused on 
assessment of 
readiness to change, 
diabetes behavior 
modification, and 
problem solving 
 
BDI: Beck Depression Inventory version I; CABG: Coronary bypass grasft surgery; CT: Cognitive Therapy; DIS: Diagnostic Interview 
Schedule; DISH: Depression Interview and Structured Hamilton; HADS: Hospital Anxiety & Depression Scale; HRSD: Hamilton 
Rating Scale for Depression; PHQ-9: Patient Health Questionnaire; SCR-90: Symptom Checklist 90 Revised; WDI: Wakefield 
Depression Inventory; ZDS: Zung Depression Scale 
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CHAPTER THREE: 
Living with Depressive Symptoms: Patients with Heart Failure 
1. Introduction 
Heart failure (HF) is a chronic syndrome that affects 5.8 million people in the 
United States1 and is the most common cause of hospitalization in elderly adults.2 Major 
depressive disorder is common in hospitalized patients with HF. One-third of 
hospitalized patients with HF suffer from major depression, and 40% of these are still 
depressed one year later.3 According to the American Psychiatric Association, a major 
depressive episode consists of five or more symptoms which are present most of the 
day for at least two weeks. One of these symptoms must be depressed mood or loss of 
interest in usual activities, and the symptoms must cause significant distress in social, 
occupational, or other areas of functioning.
Individuals can experience significant depressive symptoms without a diagnosis 
of major depressive disorder.
4 
5 Sometimes called subthreshold depression, depressive 
symptoms include depressed mood, guilt, hopelessness, low self-esteem, fatigue, sleep 
disturbances, appetite change, and inability to concentrate.6 Researchers have proposed 
that depressive symptoms lie within a continuum of depressive illness severity, which 
ranges from mild depressive symptoms to a diagnosis of major depressive disorder.7 It is 
estimated that up to 48% of outpatients with HF experience clinically significant levels of 
depressive symptoms.8 The presence of depressive symptoms has important clinical 
consequences for patients with HF. Patients with HF who have depressive symptoms 
experience reduced health-related quality of life and an increased risk of 
rehospitalization and mortality.
Although researchers have examined the predictors and outcomes of depressive 
symptoms in patients with HF, none have described the experience of living with 
depressive symptoms. Qualitative research can help researchers and clinicians 
understand a phenomenon from the patient’s point of view and guide the development of 
future interventions. The purpose of this qualitative study was to describe the experience 
of living with depressive symptoms in persons with HF. The primary research question 
was: How do persons with HF describe their depressive symptoms? Secondary research 
questions included: What factors influence depressive symptoms? What are strategies 
that persons with HF use to manage depressive symptoms? 
8,9 
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2. Methods 
2.1. Qualitative description 
This investigation was conducted using a qualitative descriptive design. 
Qualitative description involves low-inference interpretation and is often the first step in 
exploration of a phenomenon. The result is a descriptive summary of the experience in 
everyday language.10
2.2. Participants 
 This topic is particularly suited for qualitative description because 
little is known about how patients with heart failure describe their depressive symptoms. 
The study was nested in a clinical trial of biofeedback and cognitive therapy in 
patients with HF. Institutional Review Board approval was obtained prior to recruitment. 
Patients were eligible to participate if they were diagnosed with chronic HF, stable on 
cardiac medications, had no coexisting terminal illness, and had not had a stroke or 
myocardial infarction within three months.  
Purposive sampling was used to select ten outpatients who had a self-reported 
history of past or current depression, or were experiencing a clinically significant level of 
depressive symptoms, defined as a score of 14 or greater on the Beck Depression 
Inventory-II11
2.3. Data collection 
 upon enrollment in the trial (Table 3.1). Purposive sampling ensured equal 
numbers of men and women and equal representation from the intervention and control 
groups. The intervention group received six weeks of biofeedback training and cognitive 
therapy from a psychiatric nurse practitioner, while the control group received six weeks 
of attention placebo, which consisted of self-selected relaxation exercises delivered by a 
psychiatric nurse practitioner.  
One-time, semi-structured interviews were conducted in the participants’ homes 
after the intervention or placebo portion of the trial was completed. Results from two 
initial interviews found that patients had difficulty answering direct questions about 
symptoms of depression. Therefore, interviews began with questions regarding recent 
stressful events to elucidate depressive symptoms. Questions explored the participant’s 
symptoms that occurred during the stressful event. Each participant was asked to share 
techniques that they used to prevent or cope with depressive symptoms. Interviews 
lasted between 30 and 60 minutes and were audio taped. Participants were reimbursed 
$30 for their time. 
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2.4. Data analysis 
An inductive approach to content analysis was used in this study. Interviews 
were transcribed verbatim and transcriptions compared to the taped interviews to assure 
accuracy. A codebook was developed to assist in the analysis. The codebook contained 
a priori codes based on a literature review, as well as codes that emerged from the data. 
We used Atlas ti (version 5.0) to code the data. Each interview was read, re-read, and 
coded by the primary author. The transcripts were compared to ensure that coding was 
consistent throughout, and codes were first sorted into categories and then into larger 
themes. Data displays that depicted the frequencies of the codes were developed to 
assist in the reduction of the coded data into categories.12
2.5. Trustworthiness and credibility 
 The abbreviated data display 
for factors influencing depressive symptoms is provided in Table 3.2 as an example of 
the data displays used for data reduction. 
To establish trustworthiness and credibility, we used three procedures 
recommended by Creswell.13
3. Results 
 First, we clarified bias prior to data collection by bracketing 
assumptions. Bracketing assumptions consists of writing down personal assumptions 
about the phenomenon; this process allows the researcher to collect data with as 
unbiased a viewpoint as possible. Second, the coauthors met frequently throughout data 
analysis to verify the coding accurately reflected the content of the interviews. Third, the 
research results were returned to three participants to verify accuracy of the findings. 
3.1. Depressive symptoms 
 The participants’ descriptions of depressive symptoms were similar to symptoms 
of depression as defined by the Diagnostic and Statistical Manual-IV-TR criteria.4 
3.1.1. Emotional symptoms  
The 
participants described emotional symptoms of sadness, irritability, tearfulness, and 
anxiety. The participants also experienced somatic symptoms that they attributed to 
depression, including lack of energy, changes in appetite, sleep disturbances, and 
difficulty concentrating. Finally, the participants described experiencing negative thinking 
and cognitive distortions. 
Eight of the ten participants described sadness as part of their experience with 
depression. The participants used the terms “terrible sadness,” “depressed,” “moody,” 
“bad blue mood,” and “upset” to describe their mood. Six of the participants stated that 
tearfulness was a frequent symptom. One participant cried during the interview, stating: 
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 “It’s just I’m sad. And I think it’s just because there’s a lot of sad stuff. It’s just 
been really hard.” 
 Half of the participants complained of feeling irritable. They expressed feelings of 
aggravation, frustration, and anger. In many cases irritability resulted in strained 
relationships with children or spouses. As one participant said, “Sometimes I could just 
scream and one day I did, several times I have, about them not cleaning.” 
 In addition to sadness and irritability, feelings of anxiety were described by nine 
participants. The participants used “tense,” “tight,” “shaky,” “nervousness,” “worry,” and 
“fear” to describe their anxiety. One participant shared:  
 “At night I start thinking about it, the consequences of what could happen and 
what couldn’t and what would come out good, and I just, just get in a knot again.” 
3.1.2. Somatic symptoms 
Seven participants described somatic symptoms attributed to depression that 
included changes in appetite, sleep disturbances, and lack of energy. Only one patient 
described an increase in appetite while three others described a loss of appetite. Three 
of the participants described sleep disturbances. One participant in particular spent 
much of her time sleeping. At her request, the interview took place in her bedroom, while 
she sat in bed. She said, “Sometimes I just come in the room, shut the door and go to, 
and just go to sleep, just lay here.” Only three participants complained of a lack of 
energy.  
3.1.3. Negative thinking 
All ten participants described negative thinking, or self-critical thoughts.14
 “Sometimes it gets me down because I start thinking about other things... You 
know, it just kind of moves up to keep going up the ladder.” 
 
Participants described thoughts such as, “I can’t justify my existence,” “I have nothing to 
offer anymore,” and “I’m a failure.” The participants stated that the negative thoughts 
reinforced their depressed mood. As one participant shared: 
 Participants described cognitive distortions that accompanied negative thinking. 
Magnification is a cognitive distortion in which a person inflates the magnitude of the 
problem.15
 “Am I going to come out of this, am I going to die, you know is this my last time, 
or I’m going to die in there on the operating table.” 
 For example, when one participant underwent surgery, she could only think 
about the possibility of death:  
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Another frequently mentioned distortion was dwelling. Dwelling is defined as long, 
uninterrupted series of depressive thoughts that worsen depressive symptoms.15, 16
 “I think I would tell them you know from my experience, the more you dwell on it, 
the worse off you get.”  
 
When asked what advice she would give to someone in her situation, one participant 
answered: 
3.2. Stressors 
 Participants described stressors that worsened their depressive symptoms. The 
stressful experiences that the participants lived with included financial difficulties, family 
problems, health issues, and loss.  
3.2.1. Financial difficulties  
Seven participants described financial difficulties, including bankruptcy, living on 
a fixed income, and being disabled. One participant said that finances were the primary 
contributor to her depressed mood: 
 “I think the main thing well that, that upsets me is finances. If my finances get to 
the point where I get to a week before payday and I don’t have any money, then I get 
very stressed and I think that stresses everybody. But I think it especially stresses me.”  
3.2.2. Family problems  
Nine participants talked about stressful situations in their families. Problems that 
the participants dealt with ranged from children who were incarcerated, to grandchildren 
who were having problems, to alcoholism and arguments among family members. The 
participants described feeling worried about family situations and saddened or irritated 
by conflict. One participant felt depressed because he was estranged from his only child: 
“Well I felt sad there for a long time because my daughter, I wanted to be in contact with 
her and I felt hurt... I want to be somebody my daughter can depend on me being there 
when she needs me.”    
3.2.3. Health issues  
Interestingly, only five of the participants mentioned HF as influencing depressive 
symptoms. Three participants stated that depressive symptoms were present prior to the 
development of HF. One participant said that having HF did not make her depressed. 
Instead, “it’s just something else for me to be depressed about.” The majority of 
participants described other health conditions as being stressful and contributing to 
depressive symptoms. Participants described dealing with cancer, diabetes, arthritis, 
and chronic pain.  
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3.2.4. Loss  
The participants described numerous losses that worsened their depressive 
symptoms. Four of the participants described the death of a son or daughter. One 
participant had experienced the death of two children. Although some of these deaths 
had occurred years ago, it was clear that the participants still felt the effects of the loss. 
Complicating the bereavement process for these participants was the fact that all of the 
deaths were sudden. One participant said: 
 “Well of course you know it’s been in 2003 when my daughter died suddenly and I still 
haven’t gotten over that and of course at night sometimes I cry over that.” 
 Other participants did not discuss the loss of a loved one, but they experienced 
other losses. One participant described the loss associated with not being able to work: 
“I used to get really depressed.  I can’t work anymore; what am I going to? I mean, it 
really bothered me at first.” 
3.3. Strategies for managing depressive symptoms 
The overarching strategy described by the participants was “taking my mind off of 
it.” Four types of strategies were used by participants to take their minds off of 
depressive symptoms: activities, distraction, social support, and medical intervention.  
3.3.1. Activities 
Exercise was mentioned by nine participants as being an important method of 
reducing depressive symptoms. The most commonly mentioned exercise was walking. 
The participants repeatedly said that walking made them feel better, and that any 
amount of exercise was better than just “sitting around.” One participant stated:  
 “I’ve started walking. It’s fun. I put my, I take my radio and listen to my music and 
it makes me feel good because I kind of walk and do a little dance while I’m walking and 
so, so it has made me feel good when I was walking.”  
In response to the question, “What are some of the things that help you feel 
better when you feel down,” nine participants mentioned reading. The participants who 
had difficulty reading would listen to books on tape instead. As one participant said, 
“Rather than sit here and think about the bad things you know, I can get me a book to 
listen to.” For most participants, reading allowed them to “take their mind off things” and 
focus on something other than the depressive symptoms.  
Being active, or “staying busy,” was mentioned by six participants as a behavioral 
tactic that kept them from thinking about depressive symptoms. Participants used a 
variety of activities to stay busy, such as bird watching, crocheting, and watching 
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television. The simple act of getting involved in an activity helped relieve the participant’s 
depressive symptoms. 
“Sometimes I like to do crafts. I like to work crosswords and do Sudoku. Other 
times that just gets my mind off things and just concentrating on that one thing.” 
3.3.2. Distraction  
For these participants, distraction is defined as the ability to redirect one’s 
internal focus away from negative thoughts or emotions. For seven participants, 
spirituality or religiosity was an important method of distraction. Participants received 
relief by praying, attending church, and reading scripture. One participant quoted Biblical 
scriptures several times. He said, “When we fill our mind and our heart with the 
scriptures, that’s something that we can depend on.” 
A central component of spirituality was a relationship with God. One participant 
described God as “my other best friend.” Another participant said:   
 “I feel I have a great relationship to God because I talk to him about a lot of 
things and when I do, I feel better. I feel that a burden has been lifted from me; not all 
the time right away but it’s been, you know it’s been lifted.” 
When asked: “If you were talking to someone like you who felt depressed or 
down, what advice would you give them?” nine of the ten participants discussed positive 
thinking. Positive thinking is a central component of the cognitive therapy intervention 
which five of the participants had received. However, four of the five control group 
participants also discussed positive thinking. As one control group participant said:  
 “The main thing I think that I’ve found is trying to keep my mind off of things that 
make me sad.  If I find myself drifting that way, well then I know right away I’ve got to 
think of two positives. Because that’s a negative. And like I said, when you’ve got a 
negative, you’ve got to come up with two positive things to replace that.” 
 Instead of dwelling on negative thoughts, the participants redirected their 
thoughts towards the positive. One participant focused on the future: 
 “Think about the future. Think about the future; don’t dwell on the past, there’s 
nothing you can do. It’s happened; it is depressing. You know that your life has changed; 
it’s changed your life completely. But think about the positive you know, life goes on.” 
 Others focused their thoughts on affirmations. One participant read his 
affirmations out loud:  
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“My heart may be sick, but my mind and soul are strong and healthy. My 
problems are an opportunity for me to grow as a person. I’m a person of value even if I 
have heart failure, back trouble, knees and shoulder, and I’m old.”   
 Additional examples of affirmations included: “I’m alive, I’m thankful for that, I’m 
alive,” “Things are going to get better, going to get better,” and “I might not be able to do 
the things I used to do but there’s new things I can do.”   
3.3.3. Social support  
All ten participants stated that social support was an important factor in reducing 
depressive symptoms. Family and friends provided emotional, physical, and financial 
support. The married participants all provided positive descriptions of their marriages. As 
one participant said: 
 “I do appreciate that lady [indicating wife] over there. The Lord drawed us 
together and we were married after getting out of the service…Yes we celebrated our 
50th
3.3.4. Medical intervention 
 about 3 years ago. And pretty soon we’ll come up with number 54.” 
Seven of the participants (five females and two males) were taking 
antidepressants at the time of the interview, yet only four participants—all women—
mentioned antidepressants as a strategy for managing depressive symptoms. One 
participant described how antidepressants helped her enjoy sunlight again: 
“I used to hate days like today where it was sunny. Like I couldn’t stand to be in 
the sun and ever since I’ve been on antidepressants, I enjoy sunshine.”  
4. Discussion  
4.1. Discussion of findings 
The participants in this study described emotional and somatic symptoms of 
depression, as well as negative thoughts that worsened their mood. Stressors such as 
financial difficulties, family problems, and health conditions exacerbated the depressive 
symptoms. Individuals described “taking their mind off” depressive symptoms through 
activities, distraction, social support, and medical intervention.   
The depressive symptoms experienced by the participants were similar to those 
experienced by the general population with depressive symptoms. The majority of the 
sample experienced a depressed mood. This is particularly interesting since seven 
participants were currently receiving antidepressant therapy. The finding that our 
participants experienced significant emotional symptoms contrasts with results from a 
prior study in which a sample of outpatients with HF and major depression living in 
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Germany had fewer emotional symptoms of depression, as measured by the Patient 
Health Questionnaire-9 (PHQ), when compared to patients with major depression who 
did not have HF.17
Few somatic symptoms of depression were mentioned by participants. It is 
possible that the participants attributed somatic symptoms to HF rather than depression. 
Several common symptoms of HF, such as fatigue, anorexia, and sleep disturbances, 
overlap with symptoms of depression. This symptom overlap may contribute to the 
participants’ difficulty in recognizing somatic symptoms of depression.
 It is possible that the PHQ did not effectively capture the emotional 
symptoms that are experienced by patients with chronic HF. The participants in our 
study may have also been more likely to divulge emotional symptoms in their home 
environment, as opposed to a clinic or research setting.  
17 In addition, 
clinicians may also attribute somatic symptoms to HF instead of depression. This lack of 
recognition of the somatic symptoms of depression could contribute to the low treatment 
rates of depression in persons with HF,3
An important finding of this study was that negative thinking was common and 
had a detrimental impact on the participants’ mood. The presence of negative thoughts 
has been described as a characteristic of major depression.
 as well as under-treatment which results in 
individuals not receiving therapeutic doses of antidepressants.  
15 However, this was the first 
to describe negative thinking as important in patients with HF who have depressive 
symptoms. The participants experienced cognitive distortions that maintained their 
negative thought processes. Researchers have found that magnification is an 
independent predictor of depressive symptoms in the elderly.16 In addition, depressed 
patients who “dwell” on negative thoughts experience a worsened mood and are less 
able to problem solve.
The participants described a variety of stressors that worsened their depressive 
symptoms. This finding is consistent with results from other qualitative studies on living 
with HF. Investigators have found that patients with HF experience physical, emotional, 
and social turmoil in their everyday lives
18 
19, as well as multiple personal struggles and 
losses.20,21
 Many clinicians assume that patients with HF are depressed because they have 
been diagnosed with HF. However, only half of the participants mentioned HF as 
influencing depressive symptoms. Future qualitative research should explore whether 
patients with HF attribute depressive symptoms to HF. For three participants, depression 
 In combination, these studies demonstrate that having a diagnosis of HF is 
only one stressor in a life full of difficulties.  
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was something that they struggled with for years prior to the onset of HF. Pre-existing 
depression has been demonstrated to be an independent risk factor for development of 
HF.22,23
Of particular interest are the multiple strategies described to counteract 
depressive symptoms. The overarching strategy was “taking my mind off of it.” 
Participants used activities, distraction, social support, and medical intervention to 
alleviate their symptoms. Activity in the form of exercise appears to be as effective as 
antidepressants for the treatment of depression in the elderly.
 Thus, the long history of depression may have increased the risk of developing 
HF in these participants.  
24 Results from several 
small trials have shown that exercise improves depressive symptoms in patients with 
HF.
The participants’ use of social support to alleviate depressive symptoms is 
supported by the literature. Results from one study demonstrated that an increase in 
perceived social support was the only factor that predicted faster remission from 
depression in hospitalized patients with HF.
25,26 
3 In contrast, poor social support, defined as 
living alone, independently predicts the development of depressive symptoms in HF 
patients27, while single marital status also predicts depressive symptoms in patients with 
HF.
For most of the participants, spirituality was an important method of managing 
depressive symptoms. Researchers have demonstrated an inverse relationship between 
spiritual well-being and depressive symptoms in patients with chronic HF.
28 
29 In addition, 
researchers have demonstrated that older patients with HF who are involved in religious 
activities remit faster from depression than non-religious patients.
The participants used positive thinking more than any other strategy to manage 
their depressive symptoms. They also expressed that affirmations were an important 
method of reducing negative thoughts. The evidence to support positive thinking and 
affirmations as effective strategies is found in cognitive therapy, which is based on the 
Cognitive Model of depression. The Cognitive Model proposes that redirecting negative 
cognitive processes into positive ones can improve the symptoms of depression.
30 
31
Although the majority of the participants were taking antidepressants, few 
mentioned medications as a method to manage depressive symptoms. It is possible that 
 The 
use of cognitive strategies was not surprising for the five participants who received 
cognitive therapy in the parent study. However, four of the five control group participants 
also discussed positive thinking as a strategy for managing depressive symptoms.  
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participants did not view their depressive symptoms as a medical condition. Thus they 
may not have considered antidepressants as a strategy for managing depressive 
symptoms. Selective serotonin reuptake inhibitors (SSRIs) are often prescribed for 
depression in patients with HF because of the lack of cardiac side effects.32 Currently, 
there is little evidence regarding the efficacy of SSRIs for treating depression in patients 
who have HF. However, a large randomized, controlled trial is currently underway.
4.2. Limitations 
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 Because of the heterogeneity of depressive symptoms experienced by 
participants it may be necessary to obtain more viewpoints to fully understand the 
experience of living with depressive symptoms in persons with HF. Similarly, only one 
interview was conducted with each participant. Additional interviews may have revealed 
other depressive symptoms and coping strategies or provided additional insight into the 
connection between HF and depressive symptoms. This study included participants who 
experienced a cognitive therapy intervention which may have influenced participant 
experiences. This strategy can also be considered a strength because it included 
patients with a broad range of perspectives.  
5. Conclusion 
 The results of this study have important implications for clinicians and 
researchers who work with patients with HF. Given the negative outcomes associated 
with depressive symptoms, clinicians must assess hospitalized patients with HF for the 
presence of depressive symptoms as well as stressors that might exacerbate depressive 
symptoms. It also is important for clinicians and researchers to note that depression in 
patients with HF may benefit from the same interventions that are effective for treating 
depression in the general population. Participants in this study managed depressive 
symptoms through the use of activities, distraction, and social support. These strategies 
are worthy of development and testing among patients with HF in the acute care arena.  
 This study is the first to identify that negative thinking may be an important 
component of depressive symptoms in patients with HF. By targeting negative thinking, 
clinicians may be able to reduce depressive symptoms in patient with HF. Clinicians can 
teach hospitalized patients with HF to recognize negative thoughts and replace them 
with positive thoughts and affirmations. For example, an acute care nurse could ask a 
hospitalized patient with HF, “What kinds of thoughts are you experiencing right now?” 
After assessing for the presence of negative thoughts, the nurse can teach the patient 
how to replace negative thoughts with positive ones. Clinicians also may help alleviate 
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hospitalized patients’ depressive symptoms by assessing their spiritual well-being and 
referring patients with needs to appropriate spiritual care. Encouraging the patient to 
engage in activities such as ambulating or reading while they are hospitalized may also 
reduce depressive symptoms. Finally, helping patients’ significant others provide 
enhanced social support may be an important method for reducing depressive 
symptoms in patients with HF. 
Clinicians can no longer ignore the fact that patients with HF experience levels of 
depressive symptoms that reduce quality of life and increase the risk for mortality. This 
study is the first description of the experience of living with depressive symptoms in 
patients with HF. Clinicians can use the results from this study to gain understanding of 
the patients’ perspective of living with depressive symptoms. Researchers can use the 
results to develop and test interventions to reduce depressive symptoms. 
Copyright © Rebecca L. Dekker 2010
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Table 3.1: Participant characteristics 
Characteristic Percentage or Mean ± 
standard deviation  
Female  50% 
Age 62.5 ± 13.2 
Range: 37-81 years 
Minority 20% 
Married 70% 
NYHA Class I 
       Class II 
       Class III 
       Class IV 
10% 
20% 
60% 
10% 
Some college education or greater 70% 
Employed 20% 
Beck Depression Inventory –II score 18.9 ± 11.8 
Range: 7 - 40 
Antidepressant use  70% 
NYHA = New York Heart Association functional classification 
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Table 3.2: Data display for factors influencing depressive symptoms 
Code Frequency Example Quote 
Family 
problems 
9/10 “Kids and grandkids…something is always going on in 
their lives. And at least one of them always has a 
problem of some kind to deal with.” 
Loss 9/10 “Even though it’s been 11 years since my daughter died, 
I have days where I think about her a lot. I mean it never 
gets easy.” 
Finances 7/10 “We just went through a bankruptcy. And that was not 
easy. I don’t like things like that but there was nothing we 
could do.” 
Health 
problems 
8/10 “I’ve been having a lot of problems with the back, a lot of 
pain and so on. I’ve had all kinds of treatments and 
nothing works.”  
Heart 
failure 
5/10 “The only thing that stresses me really is I want to be 
able to breathe better so that I can do more around the 
house.”  
History of 
depression 
3/10 “See, I’m a person who’s fought depression all of my life, 
I mean even when I was a child.” 
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CHAPTER FOUR: 
Measurement of Negative Thinking in Patients with Heart Failure:  
A Critical Review and Analysis 
Synopsis 
1. Introduction 
The purpose of this paper is to present a critical review of the measurement of 
negative thinking to provide direction for the measurement of negative thinking in 
patients with heart failure (HF). Negative thinking can be defined as depressive 
cognitions about the self, world, future, and withdrawal from others.1 Negative thinking is 
a cognitive process that is automatic and persistent;2 it originates in childhood and 
dominates the perceptions of the depressed individual.3 Examples of negative thoughts 
include, “I’m worthless,” “Everything I do is a failure,” and “Nothing’s ever going to work 
out for me.”1 Although the content of negative thoughts is irrational, these thoughts are 
believable to the person experiencing them.
 Negative thinking has several adverse consequences in the general population. 
First, negative thinking is a risk factor for depressive symptoms,
2 
4, 5 as well as an 
independent predictor of the later development of depression among women.6, 7 Second, 
negative thinking exacerbates and maintains depressive symptoms, which contributes to 
a downward spiral of depressive symptoms that may end in major depressive disorder.2, 
8 Third, negative thinking independently predicts a worsened response to treatment for 
depression, even after controlling for history of depression and depressive symptoms at 
baseline.
 Depression is a significant clinical problem in patients with HF. Twenty percent of 
outpatients with HF suffer from major depressive disorder,
9 
10 and up to 48% of 
outpatients experience clinically significant depressive symptoms.11 Patients with HF 
who are depressed have a two-fold greater risk of death or hospitalization compared to 
patients who are not depressed.
 In a recent qualitative study, patients with HF who had depressive symptoms 
described experiencing negative thinking which exacerbated their depressed mood.
12 
13 
This finding is consistent with Beck’s Cognitive Model of depression, which proposes 
that negative thinking influences the emotional, behavioral, and somatic symptoms of 
depression.14 The patients in the qualitative study who experienced depressive 
symptoms stated that positive thinking was a strategy they used to manage depressive 
symptoms.13 Cognitive Therapy, a treatment for depression which re-directs negative 
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thoughts into positive ones, may be an effective treatment for depression in patients with 
HF.15
Therefore, the objectives of this paper were to provide an overview of the state of 
measurement of negative thinking, analyze three existing measures of negative thinking, 
and make recommendations for new directions in the measurement of negative thinking 
in patients with HF.  
 In order to test the effectiveness of Cognitive Therapy as a treatment for 
depressive symptoms in patients with HF, researchers need a valid and reliable 
measure of negative thinking in this population.  
2. Overview of the state of measurement of negative thinking 
 Negative thinking was first defined in 1967 by Beck, a psychiatrist, as the 
cognitive triad: negative thoughts about the self, world, and future.2 Since then, 
researchers have suggested a fourth type: negative thoughts about interpersonal 
relationships or withdrawal from others.
 Endorsement questionnaires are the most common method of measuring 
negative thinking.
1 
16 These questionnaires contain a list of self-statements or thoughts. 
Examples of thoughts on an endorsement questionnaire include, “I wish I were a better 
person,” “My life is a mess,” and “It’s just not worth it.”17
 Endorsement questionnaires are cost-effective, easy to administer, and quick to 
complete.
 Patients are instructed to rate 
how often they experience each thought on a Likert scale. Patients usually fill out 
endorsement questionnaires retrospectively, although a few instruments call for the 
questionnaire to be administered at the same time as a stressful stimulus.  
16 There are only a few disadvantages to using endorsement questionnaires. A 
retrospective questionnaire could lead to selective memory bias and socially desirable 
responses. It is also possible that endorsement questionnaires do not measure the 
frequency of an individual’s actual thought content, but rather the importance of the 
thought, the similarity of the thought to other ones they may have experienced, or the 
emotional salience of the thought.16, 18 However, researchers have provided evidence 
supporting the construct validity and concurrent validity of endorsement questionnaires 
for measuring negative thinking.18 As a result, endorsement questionnaires remain the 
most widely used method of measuring negative thinking in clinical trials. At least 28 
endorsement instruments have been developed to measure negative self-statements. 
Only seven of these instruments are used to measure negative thinking specific to 
depression. The other instruments measure negative thinking found in conditions such 
as anxiety, pain, eating disorders, and panic disorder.16, 18  
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 For this paper, three of the most widely used questionnaires that measure 
negative thinking in depression were selected for review. These instruments include the 
Crandell Cognitions Inventory, the Automatic Thoughts Questionnaire, and the Cognition 
Checklist- Depression subscale. The instruments are compared in Table 4.1, and 
studies which have examined their psychometric properties are described in Table 4.2.  
3. Description of three existing measures of negative thinking 
3.1. Crandell Cognitions Inventory  
The Crandell Cognitions Inventory (CCI) was developed by Crandell and 
LaPointe in 1979 to measure self-statements of depression. The authors initially defined 
depressive thoughts as the cognitive triad—negative thoughts about the self, world, and 
future. A preliminary version of the CCI was developed with a sample of psychiatric 
inpatients, psychiatric outpatients, and persons without a psychiatric illness, and it 
contained 81 negative items and 19 non-scored, positive buffer items. Individuals were 
asked to rate how frequently they experienced each thought on a scale from 1 (almost 
never) to 5 (almost always); the instructions do not give a specific time frame for thought 
recall.  
 The preliminary version of the CCI demonstrated strong evidence of reliability 
(Cronbach’s alpha = 0.98) but possible redundancy among the items. The preliminary 
version also performed well in discriminating between the three groups; however, the 
authors felt that the scale was too lengthy to be clinically useful.1
 In 1986, Crandell and Chambless
  
1
 The final version of the CCI consisted of 45 items—34 negative self-statements 
and 11 non-scored positive buffer statements. The authors intended the CCI to have 
three dimensions: negative views of the self, world, and future, but factor loadings 
revealed four dimensions: self-rated inferiority (negative view of the self), helplessness 
(negative view of the world), hopelessness (negative view of the future), and detachment 
(negative view about withdrawal from others).  
 revised the CCI with a sample of depressed 
psychiatric patients, non-depressed psychiatric patients, and normal controls. Patients 
were grouped on the basis of the following: Hamilton Rating Scale scores for 
depression, Maudsley Personality Inventory scores, whether or not the patient was 
receiving psychological treatment for depression, and whether or not patients had a 
clinical diagnosis of depression based on the Research Diagnostic Criteria.  
 The authors stated that the item-total correlations provided support for good 
internal consistency (exact correlations not reported). The Cronbach’s alpha was 0.95, 
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demonstrating evidence of strong internal consistency reliability, but possible 
redundancy among items. The sample in which the CCI was initially tested consisted of 
mostly male participants. Researchers have since used the CCI to measure negative 
thinking in college women and low-income single mothers, providing evidence of internal 
consistency of the CCI among women (Cronbach’s alpha = 0.90 and 0.97; 
respectively).4, 19
 Support for construct validity of the CCI was demonstrated by a strong 
correlation with depressive symptoms measured by the Beck Depression Inventory (r = 
0.79, p < .001).
  
1
In order to test the construct validity of the CCI among women, Crandell and 
Chambless
 Divergent validity was tested by comparing the CCI scores with a 
measurement of IQ. As expected, the authors found a moderately low correlation 
between the CCI and the IQ score (r = -0.23, p < .05), supporting divergent validity.  
1
Finally, Crandell and Chambless
 investigated the CCI in a sample of 65 outpatients with panic disorder (82% 
female), since clinically significant levels of depression are common in this population. 
The authors found a strong correlation between the CCI and the Beck Depression 
Inventory (r = 0.77, p < .001), lending support for convergent validity of the CCI among 
women. Other researchers have also found evidence for convergent validity of the CCI 
among women (see Table 4.2).  
1
3.2. Automatic Thoughts Questionnaire  
 demonstrated that the final version of the CCI 
had strong evidence of concurrent validity. The total score of the CCI correctly predicted 
the classification of 92% of the participants among the three groups: depressed 
psychiatric patients, non-depressed psychiatric patients, and normal controls. 
Hollon and Kendall17
After developing the initial items, Hollon and Kendall revised and validated the 
ATQ with a sample of 348 undergraduate students. Participants were asked to indicate 
how frequently, the thought occurred over the last week, on a scale from 1 (not at all) to 
5 (all the time). Twenty-six students were classified as having clinically significant 
depressive symptoms according to the Beck Depression Inventory. The authors found 
 developed the ATQ in 1980 to measure the frequency of 
negative automatic thoughts in individuals with depression. The authors defined 
automatic thoughts as involuntary, stream-of-consciousness cognitions. The items were 
developed by asking undergraduate students to recall a depressing event. The students 
were asked to record thoughts or self-statements that “popped into their head.” A total of 
100 items were generated for further testing.  
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that 30 items discriminated between students with and without depressive symptoms. 
These 30 items were included in the final version of the ATQ. Principal components 
analysis revealed that the scale contained four dimensions: personal maladjustment and 
desire for change, negative self-concept and negative expectations, low self-esteem, 
and giving up/helplessness. The authors state that these four dimensions reflect only 
two components of Beck’s cognitive triad: negative views of the self and future.  
Hollon and Kendall reported good evidence for internal consistency of the ATQ 
using split-half (r = 0.97) and Cronbach’s alpha (r = 0.96). Although the strong 
Cronbach’s alphas suggest there could be redundancy among the 30 items, item-total 
correlations were all significant and ranged from moderate to strong (r = 0.47 - 0.78), 
suggesting that the strong Cronbach’s alpha may reflect strong internal consistency 
rather than redundancy. Harrell and Ryon20 provided evidence for internal consistency 
reliability, but possible redundancy of the ATQ in a sample that included depressed 
outpatients and non depressed medical outpatients. Cronbach’s alpha was 0.98 for both 
the depressed and the non depressed groups, while the item-total correlations ranged 
from 0.56 to 0.91  Wong et al. also provided support for internal consistency of the ATQ 
(Cronbach’s alpha = 0.96) among a sample of Chinese patients with chronic physical 
illness.
Hollon and Kendall
21 
17
In evaluating divergent validity, Hollon and Kendall
 provided support for construct validity of the ATQ. In a 
sample of undergraduate students, participants with depressive symptoms had higher 
scores on the ATQ when compared to participants without depressive symptoms (79.6 
vs. 48.6, p < .001). Further support for the construct validity of the ATQ was found in 
moderate to strong correlations (exact correlations not reported) with the Beck 
Depression Inventory and the Minnesota Multiphasic Personality Inventory Depression 
Scale. 
17
 In contrast, Lamberton and Oei
 hypothesized that there 
would be a weak correlation between the ATQ and the State-Trait Anxiety Inventory. 
Surprisingly, there was a strong correlation (r = 0.79) between the two scales. The 
authors suggest that the lack of divergent validity of the ATQ in this sample may have 
been due to the small number of participants with depressive symptoms (8%) and the 
frequent comorbidity of anxiety and depressive symptoms. 
22 reported evidence for the divergent validity of 
the ATQ in a sample of patients with major depressive disorder. In this study, there was 
a strong correlation between the ATQ and the Beck Depression Inventory (r = 0.63), and 
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a weak correlation between the ATQ and the Beck Anxiety Inventory (r = 0.17). 
Lamberton and Oei suggest that they were able to find support for divergent validity of 
the ATQ because their sample contained large numbers of both depressed and anxious 
patients.  
Although the ATQ was originally developed with undergraduate students, Harrell 
and Ryon20 
3.3. Cognition Checklist- Depression 
provided evidence for concurrent validity of the ATQ with psychiatric 
patients. Participants were divided into three groups: a depressed psychiatric group, a 
non-depressed psychiatric group, and a non-depressed medical patient group. Group 
assignments were made on the basis of a combination of Beck Depression Inventory 
scores, the Minnesota Multiphasic Personality Inventory Depression Scale, and clinician 
depression rating scores. The ATQ scores correctly classified 93% of the patients as 
depressed psychiatric patients, non-depressed psychiatric patients, or non-depressed 
medical patients.  
Beck, Brown, Steer, Eidelson, and Riskind23 developed the Cognitive Checklist 
(CCL) in 1987 to measure the frequency of negative thinking found in depression and 
anxiety. The authors defined negative thinking of depression as automatic thoughts, 
perceptions, and images that center on negative attitudes toward the self, past and 
future. In contrast, negative thinking of anxiety was defined as automatic cognitions 
focused on a theme of danger. The authors stated that previous scales, such as the CCI 
and ATQ, did not adequately differentiate between cognitions found in depression and 
anxiety. Therefore, Beck et al.23
 Items for the CCL were derived from collections of automatic thoughts that were 
recorded by patients in daily thought diaries during Cognitive Therapy treatment. The 
preliminary version of the CCL contained a total of 43 items. In order to revise the scale 
and provide evidence of validity, the authors recruited a sample of 618 psychiatric 
outpatients. The sample was divided into two subsamples: an index sample and a cross-
validation sample. All of the patients were diagnosed according to a Structured Clinical 
Interview. Major depressive disorder was a primary diagnosis in 51% of the index 
sample and 46% of the cross-validation sample. Generalized anxiety disorder was a 
primary diagnosis in 24% of the index sample and 35.7% of the cross-validation sample.  
 designed a depression subscale (CCL-D) and an 
anxiety subscale (CCL-A) that specifically measure cognitions found in depression and 
anxiety.  
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 Participants were asked to indicate how often each thought occurred to them on 
a 5-point scale ranging from 0 (never) to 4 (always) when recalling specific situations 
(attending a social occasion, with a friend, working on a project, and experiencing pain 
or physical discomfort) and regardless of the situation. No specific time frame was given 
for the situation recall. During the revision process, the first 212 participants were also 
asked to label the predominant affect (depression or anxiety) they experienced while 
thinking each thought. A SPSS Discriminant program was used to determine whether 
each item was able to discriminate between patients with a primary diagnosis of 
depression versus anxiety. Items which discriminated between depressed and anxious 
patients were included in the CCL-D subscale only if patients labeled the thought as 
depressing. The final CCL-D subscale contained 14 items, and the CCL-A subscale 
contained 12 items. The authors conducted factor analysis with the entire CCL scale and 
found evidence for two dimensions: negative thinking of depression and negative 
thinking of anxiety. The items on the CCL-D subscale fit into only three of the five 
recalled situations: attending a social occasion, with a friend, and regardless of the 
situation.  
 Results from the cross-validation sample showed good evidence for internal 
consistency. Cronbach’s alpha for the CCL-D was 0.92, and the average item-total 
correlation was strong (r = 0.65).23 Steer et al.24
 Beck et al.
 also found good evidence for the 
internal consistency of the CCL- D in a large study that tested the psychometric 
properties of the CCL-D among undergraduate students and psychiatric outpatients 
(Cronbach’s alpha = 0.90 – 0.93). 
23
 Results from a study by Steer et al.
 provided evidence of construct validity for CCL-D. Although the 
CCL-D was correlated with both depressive symptoms and anxiety symptoms as 
measured by the Hamilton Psychiatric Rating Scales, the CCL-D was more strongly 
correlated with the depression scale (r = .62) than with the anxiety scale (r = .37). This 
lends support for both convergent and divergent validity. 
24 provide additional evidence for convergent 
and divergent validity of the CCL-D. The sample consisted of psychiatric outpatients 
diagnosed with a primary mood disorder (51.6%), a primary anxiety disorder (35.3%), or 
other psychiatric disorders (13.1%) The authors also tested the CCL-D with a sample of 
undergraduate students. The results demonstrated that the CCL-D was strongly 
correlated with the Beck Depression Inventory among both psychiatric outpatients (r = 
.66, p < .001) and undergraduate students (r = .58, p < .001). In contrast, the CCL-D had 
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a weaker correlation with the Beck Anxiety Inventory among both psychiatric outpatients 
(r = .32, p < .001) and undergraduate students (r = .37, p < .001). 
 The CCL-D has less evidence for divergent validity among patients who are 
hospitalized for a chronic physical illness. Clark, Cook, and Snow25 reported that the 
CCL-D demonstrated divergent validity among psychiatric inpatients; however, when the 
CCL-D was administered to patients who were hospitalized with a chronic physical 
illness, the CCL-D was strongly correlated with both depression and anxiety subscales 
of the Hospital Anxiety and Depression Scale (r = .60 and .69, p < .001). This indicates 
that the CCL-D may be less likely to discriminate between negative thinking of anxiety 
and depression in patients with a chronic physical illness.25
 In testing concurrent validity of the CCL, Beck et al.
  
23
 Researchers have used the CCL-D to compare levels of negative thinking 
between depressed psychiatric patients and depressed physically ill patients. Clark, 
Cooke, and Snow
 divided patients into a 
depressed group and an anxious group based on a Structured Clinical Interview and 
Hamilton Anxiety and Depression Scale scores. Patients were included in the depressed 
group if they had both a primary diagnosis of depression and a Hamilton Depression 
Scale score at least 0.5 standard deviation higher than the Hamilton Anxiety Scale 
score. Similarly, patients were included in the anxious group if their primary diagnosis 
was anxiety and their Hamilton Anxiety Scale score was at least 0.5 standard deviation 
higher than the Hamilton Depression Scale score. Using a discriminant classification 
analysis, the CCL was able to correctly classify 83% of the depressed patients and 79% 
of the anxious patients.  
25 classified patients as depressed according to the Structured Clinical 
Interview for the DSM-III.  The mean score of the CCL-D was substantially lower in the 
depressed physically ill group compared to the depressed psychiatric group (12.22 vs. 
24.24, p < 0.05). Martens et al.26 also found a low level of negative thinking among 
patients who had recently experienced a myocardial infarction and were classified as 
depressed according to a Structured Clinical Interview. The depressed post-myocardial 
infarction patients had significantly lower scores on the CCL-D compared to psychiatric 
outpatients (28 vs. 34.9, p = 0.01), after adjusting for age, sex, educational level, and 
marital status. The results from these studies raise the possibility that depressed 
patients who have recently experienced a myocardial infarction have lower levels of 
negative thinking than depressed, physically healthy patients; however, these results 
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could also indicate that the CCL-D does not effectively measure negative thinking in 
patients who are post-myocardial infarction.  
4. Comparison of the strengths and weaknesses of the measures 
    The three instruments reviewed in this paper each have strengths and 
weaknesses (see Table 4.3). All three measures have evidence for internal consistency 
reliability and four types of construct validity: factorial, convergent, divergent, and 
concurrent validity. With regard to internal consistency, all three measures demonstrated 
strong Cronbach’s alphas (greater than 0.90) among various populations, providing good 
evidence of internal consistency reliability. The strong Cronbach’s alphas could reflect 
possible redundancy, but it is also possible that these Cronbach’s alphas could be due 
to strong internal consistency rather than redundancy, as reflected in the item-total 
correlations reported by some authors.23,24
 With regard to factorial validity, a component of construct validity, each 
instrument displayed a different number of dimensions of negative thinking. The CCI 
contained four dimensions: the classic cognitive triad of negative thoughts of the self, 
world, future, plus an additional dimension—negative thoughts of withdrawal from 
others. The ATQ also displayed four dimensions; however, these dimensions reflected 
only two components of the cognitive triad: negative views of the self and future. The 
CCL as a whole showed evidence of two dimensions: negative thinking of depression 
and anxiety. The CCL-D subscale was not subjected to its own factor analysis, so it is 
not known how many dimensions of depressive negative thinking it contains.   
  
 The CCI, ATQ and CCL-D all have evidence supporting convergent validity with 
measures of depressive symptoms. The instruments also have strong support for 
concurrent validity as evidenced by the ability to discriminate between patients with and 
without depression; however, the instruments have varying levels of support for 
divergent validity. The CCI exhibited divergent validity with a measure of IQ, but the 
authors did not test its divergent validity with anxiety. The ATQ has conflicting evidence 
regarding its divergent validity with anxiety; therefore, it is not clear whether the ATQ can 
distinguish negative thoughts of depression from those of anxiety. In contrast, Beck e 
al.23
 The length of the CCI (45 items) and the ATQ (30 items) make them less 
practical for use in research and particularly in clinical settings. In addition, researchers 
 specifically designed the CCL to discriminate between negative thoughts found in 
depression and anxiety. Since then, researchers have demonstrated strong evidence of 
divergent validity of the CCL-D with anxiety among clinical and non-clinical populations.   
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have not described whether the 11 positive buffer items on the CCI are necessary. In 
contrast, the CCL-D is brief (14 items), making it easier to administer in a clinic setting or 
research trial.  
 Researchers have yet to provide strong support for the reliability and validity of 
these three measures among populations with a chronic physical condition, such as in 
patients with HF. The reliability and validity of the CCI has not been tested in patients 
with chronic physical conditions. The ATQ has been shown to have good internal 
consistency reliability among Chinese patients with a chronic physical condition, but its 
construct validity has not been tested among patients with a chronic physical condition. 
The reliability and validity of the CCL-D have been tested among patients who are 
physically ill; however, results from two studies have demonstrated that depressed 
patients who are physically ill have significantly lower mean scores on the CCL-D when 
compared to depressed psychiatric patients.25, 26
 The CCI and CCL-D were developed with a psychiatric population, while the ATQ 
was developed with undergraduate students.  Heart failure is a chronic physical 
condition that increases in prevalence with age and is the most common reason for 
hospitalization in elderly adults.
 These results may indicate that 
depressed patients with a physical illness have lower levels of negative thinking. On the 
other hand, these results could raise concerns regarding the ability of the CCL-D to 
effectively measure negative thinking in patients with a chronic physical condition such 
as HF.  
27, 28 It is possible that the ATQ’s items, generated by 
college students, may not capture negative thinking found in older patients with a chronic 
physical condition. For example, patients with HF have described negative thoughts 
such as, “I’m a burden to my family,” “I have nothing to offer anymore,” and “Useless, I’m 
just no good.”13
5. Recommendations for the measurement of negative thinking in heart failure 
 These thoughts may not be reflected by questionnaires that were 
developed in physically healthy populations; however, all three instruments have been 
tested in a variety of populations, including patients with mental illness. Therefore, it may 
only be necessary to collect more psychometric data to support the reliability and validity 
of these instruments among patients who have chronic HF.  
 In summary, the CCI, ATQ, and CCL-D have good evidence of reliability and 
validity among clinical and non-clinical populations. The CCI has the greatest potential 
for measuring negative thinking in patients with HF. This instrument has the advantages 
of being developed with a clinical psychiatric population and captures a wide range of 
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negative thinking content: negative thoughts about the self, world, future, and withdrawal 
from others. In contrast, the ATQ was developed with undergraduate students, and 
factor analysis has revealed that it only measures two components of Beck’s cognitive 
triad. Although the psychometric properties of the CCI have not been tested among 
patients with chronic physical illness, the CCI is preferred over the CCL-D because 
results from several studies raise questions regarding the construct validity of the CCL-D 
for measuring negative thinking in patients with a chronic physical condition.  
 Although the CCI demonstrated the best potential for measuring negative 
thinking in patients with HF, the CCI in its current form is too long to be clinically useful. 
Future research is needed to develop a shortened version of the CCI for use in clinical 
research and practice. It is suggested that researchers use a combination of strategies 
to determine which items to retain, including: exploratory factor analysis, corrected item-
total correlations, Cronbach’s alpha if the item were deleted, and examination of means 
and standard deviations of items to examine variability or lack thereof. 
Following the development of a shortened version of the CCI, studies are needed 
to: 1) provide evidence for internal consistency reliability of the CCI as a measure of 
negative thinking in patients with HF, 2) examine the dimensionality of the CCI via 
confirmatory factor analysis to determine if the four original dimensions are retained in a 
sample of patients with HF who have depressive symptoms, 3) provide evidence for 
convergent validity with depressive symptoms and divergent validity with anxiety among 
patients with HF, and 4) determine whether the CCI is sensitive to changes in negative 
thinking in patients with HF as a result of intervention.   
6. Conclusion 
 Negative thinking is a modifiable target for the treatment of depressive symptoms 
in patients with HF. In order to determine the effectiveness of interventions designed to 
reduce negative thinking in patients with HF, researchers need a reliable and valid 
instrument to measure negative thinking. The CCI has excellent potential for measuring 
negative thinking in patients with HF. However, research is needed to shorten the CCI 
and examine its psychometric properties of the CCI among patients with HF before it can 
be recommended for routine use to measure negative thinking in this population. 
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Table 4.1: Description of three instruments of negative thinking 
Instrument 
(Year) 
No. Items Response Options Scoring and Range Sample Item Normative Values* 
Crandell 
Cognitions 
Inventory1
34 negative 
items; 11 
positive 
buffer 
items 
 
(1986) 
Indicate the 
frequency of each 
thought on a scale 
from 1 (almost never) 
to 5 (almost always) 
Total scores are 
scored by summing 
the item responses 
to the 34 negative 
items (11 buffer 
items are not 
scored) 
Range = 34 - 170 
I’ve made 
such a mess 
of my life.  
Crandell and Chambless
• Depressed psychiatric 
patients: 116 ± 20.1 
1 
• Non-depressed psychiatric 
patients: 74.2 ± 21.4 
• Normal controls: 44.6 ± 8.3  
Automatic 
Thoughts 
Questionnaire17
30 negative 
items 
 
(1980) 
Over the past week, 
rate the frequency of 
each thought on a 
scale from 1 (not at 
all) to 5 (all the time) 
Total scores are 
calculated by 
summing the 30 item 
responses 
Range = 30-150 
It’s just not 
worth it.  
Hollon and Kendall
• Depressed college students: 
79.6  ± 22.3 
17 
• Non-depressed college 
students: 48.6 ± 10.9  
Dozois et al.29
• Elderly: 41.6 ± 13.7 
  
• Women: 53.5 ± 18.6 
• Men: 48.4 ± 16  
Harrell and Ryon
• Depressed psychiatric 
outpatients: 88.9 ± 21.2 
20 
• Non-depressed psychiatric 
outpatients: 42.4 ± 10 
• Non-depressed medical 
outpatients: 38.4 ± 8.2  
Cognition 
Checklist- 
Depression23
14 items 
 
(1987) 
Frequency of each 
thought on a scale 
from 1 (“never”) to 5 
(“always”)Indicate 
how often each 
Total scores are 
calculated by 
summing the 14 
responses  
Range = 14-70 
I don’t 
deserve to be 
loved.  
Beck et al.
• Depressed psychiatric 
outpatients: 54.8 ± 9 
23 
• Anxious psychiatric 
outpatients: 45 ± 7.7  
Table 4.1 (Continued) 
 
56 
Instrument 
(Year) 
No. Items Response Options Scoring and Range Sample Item Normative Values* 
thought occurs on a 
5-point scale ranging 
from 0 (never) to 4 
(always) during 
specific situations 
(being with a friend 
or attending a social 
occasion) or 
regardless of the 
situation. No specific 
time frame is given 
for the situation 
recall. 
Martens et al.
• Depressed psychiatric 
outpatients: 34.9 ± 11.9 
26 
• Depressed post-MI patients: 
28 ± 9.6 
• Non-depressed post-MI 
patients: 17.8 ± 8.5  
Clark et al.
• Depressed hospitalized 
medical patients: 12.2 ± 9.1 
25 
• Non-depressed hospitalized 
medical patients: 5.1 ± 7.2 
• Healthy controls: 4.5 ± 6.2  
*Normative values are given as mean ± standard deviation 
Table 4.2 (Continued) 
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4.2: Psychometric properties of three measures of negative thinking 
First Author 
(date) 
Purpose Design Sample Reliability Evidence of 
Validity 
Comments 
Crandell Cognitions Index (CCI) 
Crandell1 To develop a 
measure of 
depressive self-
statements 
 
(1980) 
Cross-sectional N = 212 
Psychiatric 
depressed group, 
psychiatric non-
depressed group, 
normal control 
group 
Females 16% 
Cronbach’s 
alpha = 
0.95 
Concurrent validity, 
convergent and 
divergent validity, 
and factor validity 
were supported 
The authors did 
not describe 
support for 
content validity; 
however, items 
were developed 
based on Beck’s 
Cognitive Model 
of Depression 
Crandell1 To test the 
validity of the 
CCI among 
women 
 
(1980) 
Cross-sectional N = 65 Outpatients 
with agoraphobia 
with panic disorder 
Female 82% 
Not 
reported 
Convergent validity 
was supported: CCI 
was strongly 
correlated with the 
BDI 
This study was 
reported in the 
same journal 
article as above 
Peden7 To test the 
effectiveness of 
a cognitive 
behavioral 
group 
intervention on 
depressive 
symptoms 
 
(2000) 
Experimental, 
repeated-
measures  
N = 92 
College women 
 
Cronbach’s 
alpha = 
0.95-0.97 
Not reported The intervention 
group 
experienced a 
significant 
decrease in CCI 
scores at one  
month and six 
months  
Peden4 To determine 
predictors of 
depressive 
symptoms in 
 
(2004)  
Cross-sectional N = 205 
Low-income single 
mothers  
Cronbach’s 
alpha = 
0.97 
Convergent validity: 
CCI strongly 
correlated with the 
BDI, CES-D, 
Divergent 
validity was not 
evaluated in this 
study.  
Table 4.2 (Continued) 
 
58 
First Author 
(date) 
Purpose Design Sample Reliability Evidence of 
Validity 
Comments 
low-income 
single mothers 
Everyday Stressors 
Index, and 
Rosenberg Self-
Esteem Scale 
Peden30 To test a 
cognitive 
behavioral 
group 
intervention on 
depressive 
symptoms 
 
(2005)  
Experimental, 
repeated 
measures 
N = 136 
Low income, single 
mothers 
Cronbach’s 
alpha = 
0.94-0.97 
Not reported The authors 
found a 
decrease in 
negative thinking 
in the 
intervention 
group at one 
month and six 
months 
Automatic Thoughts Questionnaire (ATQ) 
Hollon17 To develop an 
instrument that 
measures 
automatic 
thoughts of 
depression 
 
(1980) 
Cross-sectional N = 348 
College students 
Female 42% 
 
Split half 
coefficient = 
0.97; 
coefficient 
alpha = 
0.96; 
item-total 
correlations 
ranged from 
0.47  to 
0.78 
Convergent validity 
was supported but 
divergent validity 
(with anxiety) was 
not supported. 
Factor validity was 
supported. 
There was a low 
percentage of 
students with 
depressive 
symptoms 
(7.5%); 
depression was 
not diagnosed 
with a diagnostic 
interview 
Dobson31 To test the 
psychometric 
properties of 
 
(1983) 
Cross-sectional N = 456 
College students 
Female 49% 
Cronbach’s 
alpha = 
0.96 
 Convergent validity 
was supported: the 
ATQ was strongly 
The ATQ had 
stronger support 
for construct 
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First Author 
(date) 
Purpose Design Sample Reliability Evidence of 
Validity 
Comments 
three cognitive 
assessment 
scales 
(males) and 
0.95 
(females) 
correlated with the 
BDI (r = 0.62, p < 
.001)  
validity and 
reliability than 
two other 
cognitive 
measures: the 
Dysfunctional 
Attitude Scale 
and the 
Interpretation 
Inventory 
Harrell20 To test the 
psychometric 
properties of 
the ATQ in a 
clinical sample 
 
(1983) 
Cross-sectional N = 61 
Adult outpatients 
divided into three 
groups: 
depressed, non-
depressed 
psychiatric, and 
non-depressed 
patients who were 
seeking medical 
care 
Female 56% 
Split-half 
coefficient = 
0.96 
Cronbach’s 
alpha = 
0.98 
Item-total 
correlations 
ranged from 
0.56 to 0.91 
(p = .001) 
Convergent validity 
was supported: 
depressed patients 
had higher ATQ 
scores than non-
depressed patients. 
Concurrent validity 
was supported: ATQ 
correctly classified 
93.1% of patients. 
Patients were 
separated into 
groups based on 
BDI scores and 
a clinical 
depression 
rating given by a 
therapist  
Lamberton22 To determine 
whether anxiety 
and depression 
can be 
differentiated 
by thought 
content 
 
(2008) 
Cross-sectional N = 135 
Outpatients with 
depressive 
disorder, anxiety 
disorder, or both 
Female 55% 
Not 
reported 
Convergent and 
divergent validity 
were supported: 
ATQ was strongly 
correlated with BDI 
(r = 0.63, p < .05) 
and weakly 
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First Author 
(date) 
Purpose Design Sample Reliability Evidence of 
Validity 
Comments 
correlated with the 
Beck Anxiety 
Inventory (r = 0.17, 
p < .05) 
Wong21 To test the 
efficacy of 
cognitive 
behavioral 
group therapy 
on depressive 
symptoms in 
patients with 
chronic 
physical illness 
(2007) Randomized, 
controlled trial 
N = 73 
Chinese patients 
with chronic 
physical illness 
Female 75%  
Cronbach’s 
alpha = 
0.96 
Not reported The authors 
used a Chinese 
version of the 
ATQ but did not 
specify how it 
was translated 
and validated 
Cognition Checklist- Depression subscale (CCL-D) 
Beck23 To develop and 
test the 
psychometric 
properties of 
the CCL 
 (1987) Cross-sectional N = 618 
Outpatient 
psychiatric patients 
Female 55% 
Cronbach’s 
alpha = 
0.92; 
Average 
corrected 
item-total 
correlation 
= 0.65; 
Test-
reliability 
was tested 
by 
administerin
Convergent and 
divergent validity 
were supported: the 
CCL-D was strongly 
correlated with the 
HAM-D (r = 0.62, p 
< .001) and weakly 
correlated with the 
HAM-A (r = 0.37, p < 
.001). 
Concurrent validity 
was supported: the 
CCL-D correctly 
The CCL also 
contains an 
anxiety subscale 
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First Author 
(date) 
Purpose Design Sample Reliability Evidence of 
Validity 
Comments 
g the CCL-
D to 66 
patients 
after six 
weeks: the 
correlation 
between the 
two scores 
was 0.76 (p 
< .001) 
classified 83% of 
depressed patients 
Steer24 To test the 
psychometric 
properties of 
the CCL in 
psychiatric 
outpatients and 
university 
students 
 
(1994) 
Cross-sectional N = 2,197  
Psychiatric 
outpatients (n = 
1,907) and 
university students 
(n = 290) 
Female 58% 
Cronbach’s 
alpha = 
0.91-0.93; 
Item-total 
correlations 
ranged from 
0.56 to 0.85 
in the 
psychiatric 
sample and 
0.41 to 0.72 
in the 
student 
sample 
Factor analysis 
supported the 
original two 
dimensions (anxiety 
and depression) 
only in the outpatient 
group. 
Construct validity 
was supported: the 
CCL-D was strongly 
correlated with the 
BDI and HAM-D, but 
only weakly 
correlated with the 
Beck Anxiety 
Inventory and HAM-
A. 
The results from 
this study 
provide 
additional 
support for the 
strong 
convergent and 
divergent validity 
of the CCL-D.  
Clark25 To compare 
depressive and 
 (1998) Cross-sectional N = 152 
Depressed 
Not 
reported 
Among medical 
patients, convergent 
The CCL-D has 
stronger support 
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62 
First Author 
(date) 
Purpose Design Sample Reliability Evidence of 
Validity 
Comments 
anxious 
symptoms 
among 
physically ill 
patients and 
depressed 
psychiatric 
inpatients 
psychiatric 
inpatients (n = 75), 
hospitalized 
medical patients 
with chronic 
physical illness (n 
= 52), healthy 
controls (n = 25) 
Female 59% 
validity was 
supported but not 
divergent validity; 
the CCL-D was 
strongly correlated 
with the BDI and the 
HADS-D (r = 0.77, 
0.60, p < .001), but it 
was strongly 
correlated with 
measures of anxiety 
such as the HADS-A 
(r = 0.69, p < .001). 
In contrast, the CCL-
D showed good 
evidence of 
convergent and 
divergent validity in 
psychiatric 
inpatients; the CCL-
D was weakly 
correlated with 
HADS-A (r = 0.29, p 
< .05).  
for divergent 
validity among 
psychiatric 
patients 
compared to 
medical patients.  
Martens26 To describe 
level of 
negative 
thinking in 
patients who 
 
(2006) 
Cross-sectional N = 120 
Non-depressed 
post MI patients (n 
= 40), depressed 
post MI patients (n 
Not 
reported 
Not reported The depressed 
post-MI patients 
had lower levels 
of negative 
thinking than 
Table 4.2 (Continued) 
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First Author 
(date) 
Purpose Design Sample Reliability Evidence of 
Validity 
Comments 
are post MI = 40), and 
depressed 
psychiatric 
outpatients (n = 
40) 
Females = 38% 
psychiatric 
outpatients (28 
vs. 34.9, p = 
.013) after 
controlling for 
age, sex, 
education, and 
marital status 
BDI = Beck Depression Inventory; CES-D = Center for Epidemiologic Studies Depression scale; HAM-A = Hamilton Rating Scale for 
Anxiety; HAM-D = Hamilton Rating Scale for Depression; HADS-A = Hospital Anxiety and Depression Scale- Anxiety subscale; 
HADS-D = Hospital Anxiety and Depression Scale- Depression subscale, MI = myocardial infarction 
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Table 4.3: Strengths and weaknesses of the three measures 
 Strengths Weaknesses 
Crandell 
Cognitions 
Inventory 
• Captures four dimensions of negative 
thinking 
• Evidence for internal consistency 
• Evidence for convergent and 
concurrent validity 
• Developed with a clinical psychiatric 
population 
 
• Psychometric properties have not been tested among 
patients with chronic physical illness 
• Divergent validity with anxiety has not been tested 
• Possible redundancy 
• Length (45 items) 
Automatic 
Thoughts 
Questionnaire 
• Evidence for internal consistency  
• Evidence for convergent, divergent, 
and concurrent validity 
• Validity has not been tested in patients with chronic 
physical illness 
• Developed with healthy undergraduate students 
• Captures only two dimensions of the cognitive triad 
• Possible redundancy 
• Length (30 items) 
Cognitive 
Checklist- 
Depression 
• Evidence for internal consistency 
• Evidence for convergent, divergent, 
and concurrent  validity 
• Brevity (14 items) 
• Developed with a clinical psychiatric 
population 
• Possible redundancy  
• Evidence for lack of divergent validity among patients with 
chronic physical illness 
• Depressed patients with a chronic physical illness have 
lower scores on the CCL-D than depressed psychiatric 
patients, raising questions regarding its validity among 
patients with chronic physical conditions 
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CHAPTER FIVE: 
Evaluating the Psychometric Properties of a Measure of Negative Thinking in  
Patients with Heart Failure 
1. Introduction 
 Heart failure (HF) is a chronic condition which is increasing in prevalence and 
incidence worldwide.1 Depressive symptoms are common in patients with HF; up to 48% 
of patients with HF experience symptoms of depression,2 while 20% have major 
depressive disorder.3 Both depressive symptoms and depression have a profound effect 
on morbidity, mortality, and health-related quality of life among patients with HF.2 
Patients with HF who experience depressive symptoms have a two-fold increase in the 
risk of death compared to patients who do not have depressive symptoms.3
Negative thinking is a type of cognition in which the individual experiences 
automatic, repetitive thoughts regarding the self, world, future, and withdrawal from 
others.
  
4, 5 Negative thinking is a risk factor for depressive symptoms,6, 7 and the presence 
of negative thinking in major depressive disorder lessens the response to treatment for 
depression.8 In a qualitative study, we found that patients with HF who have depressive 
symptoms described experiencing negative thinking, which worsened the depressed 
mood. Examples of negative thoughts described by patients with HF who were 
experiencing depressive symptoms include “I have nothing to offer anymore,” “I’m a 
failure,” and “I can’t justify my existence.”
Cognitive therapy, which focuses on the reduction of negative thinking, was 
developed by Beck in 1967 and has been shown to be an effective treatment for 
depression in the general population.
9 
4, 10 Cognitive therapy is based on Beck’s cognitive 
model of psychopathology.11 The main tenet of the cognitive model is that each 
psychological disorder has a distinct cognitive content. For example, negative thinking of 
depression focuses on negative thoughts about the self, world and future, while negative 
thinking of anxiety focuses on a theme of danger. Researchers have proposed that 
cognitive therapy may be an effective treatment for depressive symptoms in patients 
with HF.12
The Crandell Cognitions Inventory (CCI) has been used to measure negative 
thinking in psychiatric outpatients, healthy adults,
 However, in order to test the effects of cognitive therapy on depressive 
symptoms in patients with HF, researchers need a reliable and valid instrument for 
measuring negative thinking in this population.  
5 low income single mothers,6 and 
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college women.13
2. Methods 
 There is no evidence for the reliability and validity of this instrument as 
a measure of negative thinking in patients with chronic HF. Furthermore, researchers 
have not tested the divergent validity of the CCI with anxiety. Therefore, the purpose of 
this study was to evaluate psychometric properties of the Crandell Cognitions Inventory 
among patients with HF. The specific aims of this study were to 1) determine the 
reliability and internal consistency of the CCI, and 2) evaluate the construct validity of the 
CCI by examining the dimensionality of the CCI and testing the following hypotheses in 
patients with HF: (a) patients with depressive symptoms will have higher levels of 
negative thinking than patients without depressive symptoms, (b) patients will 
demonstrate a dose-response relationship between depressive symptoms and negative 
thinking, and (c) the correlation between the CCI and depressive symptoms will be 
stronger than the correlation between the CCI and anxiety symptoms.  
2.1. Design  
This study was nested in a clinical trial testing biofeedback and cognitive therapy 
in patients with HF (Biobehavioral Intervention in Heart Failure, NIH, NINR R01 
NR008567). Institutional Review Board approval was obtained both for the original study 
and this data analysis. Only baseline data were used for data analysis.  
2.2. Sample and setting 
The sample consisted of 179 outpatients with a confirmed diagnosis of impaired 
left ventricular systolic HF or preserved systolic function HF. Patients were recruited 
from June 2004 to May 2009 from the cardiology clinic at an academic medical center as 
well as a Veteran’s Administration cardiology clinic. Patients were eligible for enrollment 
if they were on stable doses of HF medications for at least three months and were not 
referred for cardiac transplantation. Patients were excluded for valvular or peripartum HF 
etiology, myocardial infarction or stroke within the past three months, major stroke 
sequelae, or coexisting terminal illness. Informed consent was obtained and patients 
completed questionnaires at a General Clinical Research Center. Research associates 
were present at all times to answer questions and confirm that no items were 
inadvertently skipped.  
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2.3. Measures 
2.3.1. Negative thinking  
Negative thinking was defined as cognitions about the self, world, future, and 
withdrawal from others, and was measured using the Crandell Cognitions Inventory 
(CCI).5
The CCI was developed by Crandell and LaPointe in 1979 with a sample of 
depressed psychiatric patients, non-depressed psychiatric patients, and normal 
controls.
 The CCI is a 45-item scale that contains of 34 negative items and 11 positive, 
non-scored, “buffer” items. Patients are asked to endorse how frequently they 
experience a thought on a scale from 1 (almost never) to 5 (almost always). Total scores 
are calculated by summing the item responses to the 34 negative items. Higher scores 
indicate a greater frequency of negative thinking.  
5 Researchers have demonstrated strong evidence for the reliability of the CCI 
among psychiatric patients, healthy adults, college women, and single mothers.5, 6, 13 
Crandell and Chambless5
Researchers have examined the validity of the CCI using factor analysis, 
criterion-related validity and construct validity.
 stated that the CCI displayed good internal consistency; 
however, item-total correlations for the CCI have not been reported.  
5 Crandell and Chambless theorized that 
the CCI would have three dimensions with factor analysis: negative thoughts about the 
self, world, and future. However, factor loadings revealed four dimensions: self-rated 
inferiority, helplessness, hopelessness, and detachment from others. These results led 
Crandell and Chambless to add negative thoughts about withdrawal from others to their 
conceptual definition of negative thinking.5
Crandell and Chambless have found good evidence for criterion-related and 
construct validity of the CCI.
  
5 The CCI was able to correctly predict the classification 
(depressed psychiatric patients, non-depressed psychiatric patients, and normal 
controls) of 92.5% of the sample. Construct validity was tested with convergent and 
divergent validity; researchers demonstrated that the CCI strongly correlates with 
depressive symptoms as measured by the Beck Depression Inventory.5, 6 Crandell and 
Chambless5 also found evidence that the CCI has divergent validity with measures of 
IQ.5 However, researchers have not explored the divergent validity of the CCI with 
regards to anxiety symptoms.  
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2.3.2. Depressive symptoms  
Depressive symptoms were defined as clinically significant symptoms of 
depression that can exist with or without the presence of major depressive disorder.14 
The Beck Depression Inventory version II (BDI)15 was used to measure depressive 
symptoms. The BDI is a 21-item questionnaire that assesses the presence and severity 
of depressive symptoms. Patients who score greater than 13 are considered to have 
clinically significant depressive symptoms. BDI scores can also be used to categorize 
people into 4 groups; those with no symptoms (0-13), mild (14-19), moderate (20-28), 
and severe depressive symptoms (29-63). The original version of the BDI has been 
shown to predict mortality and hospitalizations in patients with HF.16
2.3.3. Anxiety symptoms 
 The Cronbach’s 
alpha for our sample was 0.88, providing evidence of adequate reliability.  
Anxiety symptoms were defined as the negative emotional response to a 
perceived threat.17 Anxiety symptoms were measured with the state anxiety subscale of 
the Brief Symptom Inventory (BSI).18 The BSI anxiety subscale consists of six items. 
Patients rate each symptom on a 5-point scale (0-4) of distress ranging from 'not at all' to 
'extremely'. Item scores are summed and the mean obtained. The possible range of 
mean scores for the subscale is 0 to 4, with higher scores indicative of higher levels of 
anxiety. Researchers have demonstrated evidence for internal consistency, reliability, 
factor validity, and construct validity of the BSI anxiety subscale among medically ill 
patients.
2.4. Data analysis 
18, 19 
Data analysis was conducted using SPSS version 16. The baseline 
characteristics of the sample were described using percentages, means, and standard 
deviations. The homogeneity or internal consistency of the CCI was assessed using 
Cronbach’s alpha. Alpha coefficients greater than 0.70 were considered to indicate 
adequate internal consistency, while coefficients greater than 0.90 were considered to 
indicate item redundancy. Corrected item-total correlations were also used to determine 
the internal consistency of the CCI. An acceptable coefficient for item-total correlations 
was greater than 0.20.
Dimensionality was assessed using principal components analysis with direct 
oblimin rotation because correlations between factors were assumed. Factors would be 
20 
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retained for rotation if they had an eigenvalue of greater than one, and if the factors were 
located above the elbow on the scree plot.  
To further assess construct validity of the CCI, we tested three hypotheses. First, 
independent t-test was used to determine whether patients with depressive symptoms 
had higher levels of negative thinking than patients without depressive symptoms. 
Second, one-way analysis of variance and post-hoc comparisons using the Tukey HSD 
test were used to evaluate whether patients demonstrate a dose-response relationship 
between depressive symptoms and negative thinking. Third, Pearson correlation 
coefficients were used to test the relationships among CCI scores, depressive 
symptoms, and anxiety symptoms. 
3. Results 
3.1. Sample characteristics 
Sample characteristics are described in Table 5.1. The mean level of negative 
thinking in our sample was 58.6 ± 24.7. The potential range for the CCI is 34 to 170; the 
range for our sample was 34 to 158. Approximately 24% of the sample (n = 42) 
experienced clinically significant depressive symptoms based on BDI scores.  
3.2. Reliability 
Cronbach’s alpha for the CCI was 0.96, indicating adequate internal consistency, 
but possible redundancy of items. The corrected item-total correlations for each of the 
items were all greater than 0.4, indicating that each of the items contributed to the scale 
(Table 5.2).  
3.3. Construct validity  
3.3.1. Principal components analysis  
The 34 items were subjected to principal components analysis. Based on the 
scree plot, one primary component emerged that explained 46% of the variance (see 
Figure 5.1). Three other components had eigenvalues greater than 1. These 
components explained an additional 5%, 4%, and 3% of the variance. When the 
component matrix was examined, all of the items loaded strongly on the first component. 
A few items loaded on components two through four but these loadings were weaker 
than the loadings for the first component. Additionally, only one factor was located above 
the elbow on the scree plot. These results indicate that the CCI exhibited only one 
component; therefore, direct oblimin rotation was not performed. 
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3.3.2. Hypothesis testing 
The level of negative thinking among patients with depressive symptoms was 
higher than that of patients without depressive symptoms (86.7 ± 25 vs. 50 ± 26, p < 
.001). There was a dose-response relationship between depressive symptoms and 
negative thinking. Patients with mild moderate, and severe depressive symptoms had 
progressively higher levels of negative thinking when compared to patients with no 
depressive symptoms, providing evidence for convergent validity (F = 61.8, p < .001). 
Post-hoc tests revealed significant differences in levels of negative thinking between 
each of the groups (see Figure 5.2). The correlation between negative thinking and 
depressive symptoms (r = .732, p = .01) was slightly higher than that of negative thinking 
and anxiety symptoms (r = .595, p = .01), providing evidence for divergent validity.  
4. Discussion 
 This was the first study to examine the psychometric properties of an instrument 
that measures negative thinking in patients with HF. The results of our study 
demonstrate that the CCI has adequate internal consistency and reliability in patients 
with HF. However, the high Cronbach’s alpha suggests that there may be redundancy in 
the items. The CCI contains 45 items and is longer than other measures of negative 
thinking, such as the Cognitions Checklist- Depression scale (14 items).11
Only one strong component emerged in our principal components analysis. Our 
findings contrast with those of Crandell and Chambless,
 To improve 
the clinical and research utility of the CCI, future researchers should develop and test 
the reliability and validity of a shortened version. Researchers also should identify 
whether the non-scored, positive buffer items are necessary.  
5 who found that the CCI 
contained four components—negative thoughts about the self, world, future, and 
withdrawal from others.5
We hypothesized that patients with depressive symptoms would have higher 
levels of negative thinking compared to patients without depressive symptoms. 
Furthermore, we hypothesized that patients with mild, moderate, and severe depressive 
symptoms would have progressively higher levels of negative thinking compared to 
 It is possible that we were unable to adequately assess the 
dimensionality of the CCI due to a relatively small number of patients in our study with 
clinically significant depressive symptoms (n = 42). Additional factor analyses of the CCI 
that include samples of patients with HF who have a high level of depressive symptoms 
are needed.  
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patients with no depressive symptoms. Our findings supported both hypotheses.  Most 
compelling was the dose-response relationship between negative thinking and 
depressive symptoms. The observation that as levels of negative thinking increase 
severity of depressive symptoms increased accordingly provides strong support for the 
convergent validity of the CCI among patients with HF.  
Finally, we provided evidence for divergent validity of the CCI with regards to 
anxiety symptoms. Evidence of divergent validity with anxiety is important because in the 
cognitive model, Beck proposes that depression and anxiety have separate, distinct 
content.21 Thus a valid measure of depressive negative thinking in patients with HF 
should be more strongly correlated with depressive symptoms than anxiety symptoms. 
In our sample of patients with HF, the CCI was strongly correlated with both depressive 
symptoms and anxiety symptoms. It is possible that the strong correlation between the 
CCI and both measures reflects frequent comorbidities of depressive symptoms and 
anxiety in patients with HF.22
Finally, one limitation should be noted. We did not use a diagnostic interview to 
categorize patients as depressed or non-depressed. Therefore, we could not evaluate 
the concurrent validity of the CCI by testing its ability to distinguish levels of negative 
thinking between depressed and non-depressed patients with HF. The inclusion of a 
diagnostic interview for major depressive disorder would be beneficial in future 
psychometric analyses of a shortened version of the CCI.  
 However, the correlation between the CCI and depressive 
symptoms was slightly stronger than that of the CCI and anxiety, providing some support 
for divergent validity of the CCI with anxiety symptoms.  
5. Conclusion 
The findings from our study provide strong support for the reliability and validity 
of the CCI as a measure of negative thinking in patients with HF. Depressive symptoms 
remain a significant clinical problem in patients with HF, and negative thinking is a 
potential target for the treatment of depressive symptoms in this population. We 
recommend the CCI for use in research studies testing interventions that target the 
reduction of negative thinking in patients with HF. Ongoing research in our group is 
focused on determining whether CCI scores change over time as a result of 
interventions that target negative thinking in both outpatients and inpatients with HF. We 
also plan to develop and test a shortened version the CCI by eliminating redundant 
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items. A shortened version will improve the CCI’s clinical practicality as a measure of 
negative thinking among patients with acute and chronic HF. 
Copyright © Rebecca L. Dekker 2010
 73 
Table 5.1: Sample characteristics (N = 179) 
Characteristic Frequency (%) or 
mean ± standard deviation 
Female 59 (33%)  
Age 60 ± 13 
Married 94 (52.5%) 
Minority 35 (19.6%) 
Education level  
      Less than high school 34 (19%) 
      High school graduate 44 (24.6%) 
      Some college or greater 103 (56.4%) 
Employment status  
      Employed 47 (26.3%) 
      Disability 36 (20.1%) 
      Retired 84 (47%) 
Body Mass Index 32.5 ± 8.3 
NYHA functional class  
      Class I 15 (8.4%) 
      Class II 75 (41.9%) 
      Class III 71 (39.7%) 
      Class IV 13 (7.3%) 
Left ventricular ejection fraction 36.6 ± 14.8 
Ischemic HF etiology 79 (44.1%) 
Current smoker 31 (17.3%) 
Months since diagnosed with HF 77 ± 84 
Comorbidities  
      Prior myocardial infarction 88 (49.2%) 
      Atrial fibrillation 78 (43.6%) 
      Implanted cardiac defibrillator 63 (35.2%) 
      Stroke 38 (21.2%) 
      Chronic obstructive pulmonary 
disease 
32 (17.9%) 
      Diabetes 79 (44.1%) 
Medications  
      ACE inhibitor 127 (70.9%) 
      Beta blocker 157 (87.7%) 
      Antidepressant 42 (23.5%) 
Crandell Cognitions Inventory 58.6 ± 24.7 
Beck Depression Inventory-II 9.9 ± 8.2 
Brief Symptom Inventory- anxiety 
subscale 
0.61 ± 0.69 
NYHA = New York Heart Association, HF = Heart failure, ACE = Angiotensin-converting 
enzyme 
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Table 5.2: Item-total correlations for the Crandell Cognitions Inventory (N = 152) 
Item Corrected 
item-total 
correlation 
Cronbach’s 
alpha if item 
deleted 
1. I’m just a nobody .555 .963 
3. I’ll never feel good again .574 .963 
4. I sure have wasted the opportunities in my life .722 .962 
5. I don’t know what I should do .662 .963 
6. I’m always letting myself down .772 .962 
8. I’ve made such a mess of my life .703 .962 
10. Nothing ever works out for me anymore .700 .962 
11. Things really look hopeless .675 .963 
12. Why can’t I be happy? .778 .962 
13. It all seems so useless .765 .962 
15. I just don’t cut it .739 .962 
16. I sure am bored .475 .964 
17. My life is so confused, I’ll never straighten it out .786 .962 
18. I’m a burden to m family .605 .963 
20. I’ll never be happy with myself .702 .962 
22. There’s no way out of this mess .625 .963 
23. I don’t seem to have the energy to get through the 
day .639 .963 
24. I really can’t do what’s expected of me .680 .963 
26. No one can know how alone I feel .661 .963 
27. I’ll never do as well as others .624 .963 
28. Everything I do is a failure .698 .963 
29. I don’t even feel like going out of the house .533 .964 
30. I’m a real disappointment to my family .687 .963 
32. I feel so detached; I just can’t communicate .658 .963 
33. I mess everything up .727 .963 
35. I know what I should do but I just can’t do it .554 .964 
36. Nothing’s ever going to work out for me .717 .962 
37. I feel trapped .739 .962 
38. Daytimes are bad but nighttimes are terrible .622 .963 
39. I just wish it would be all over .600 .963 
41. Nothing seems exciting anymore .599 .963 
43. I wish people would just leave me alone .540 .963 
44. Nobody cares about me .603 .963 
45. I feel so helpless .654 .963 
 
 75 
Figure 5.1: Scree plot of factors of the Crandell Cognitions Inventory in patients 
with heart failure  
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Figure 5.2: Dose-response relationship between depressive symptoms and 
negative thinking in outpatients with heart failure*  
 
*One-way analysis of variance, F = 61.8, p < .001 
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C = D p = .003 
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Chapter Six:  
A Brief Cognitive Therapy Intervention Improves Outcomes in Hospitalized 
Patients with Heart Failure: A Randomized, Controlled Pilot Study 
1. Introduction 
 Hospitalized patients with HF are at high risk for experiencing depression and 
depressive symptoms. One-third of patients hospitalized with HF suffer from major 
depressive disorder.1 The adverse effects of major depressive disorder and depressive 
symptoms on mortality and morbidity in patients with HF have been well documented.2-6 
In a meta-analysis, Rutledge et al. demonstrated that patients with HF and depressive 
symptoms were twice as likely to die or experience a cardiac event when compared to 
patients without depressive symptoms.3 Other researchers have found patients with HF 
who report depressive symptoms during hospitalization are at higher risk for both short-
term and long-term mortality.2, 7 Depressive symptoms also have a negative impact on 
health-related quality of life (HRQOL) among patients with HF.4
Negative thinking, a modifiable risk factor for depressive symptoms, is a potential 
target for intervention in patients with HF. Negative thinking, first described by Beck,
 Interventions to treat 
depressive symptoms in patients with HF are needed to improve survival and HRQOL. 
8 
can be defined as automatic and persistent negative cognitions about the self, world, 
future, and interpersonal relationships.8, 9 In Beck’s cognitive model of depression, it is 
postulated that negative thinking influences the emotional, behavioral, and somatic 
symptoms of depression.10
Negative thinking has several adverse consequences in the general population. 
First, negative thinking has been described as a risk factor for depressive symptoms.
  
11, 12 
Second, negative thinking exacerbates and maintains depressive symptoms, which 
contributes to a downward spiral of worsening depressive symptoms that may end in 
major depressive disorder.8, 13 Third, researchers have found that the presence of 
negative thinking independently predicts a diminished response to treatment for 
depression after controlling for history of depression and depressive symptoms at 
baseline.14
Cognitive therapy (CT), the psychotherapeutic intervention based on the 
cognitive model, alters depressive symptoms by redirecting negative thinking. CT has 
been used successfully to treat depression in multiple populations.
  
10, 15 Results from 
previous studies indicate that brief CT interventions that use of thought-stopping and 
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affirmations to decrease the level of negative thinking reduce depressive symptoms in 
women at risk for depression.16, 17
The availability of a clinically feasible intervention that could be offered at the 
bedside may increase clinicians’ ability to treat depressive symptoms in hospitalized 
patients with HF. One potential, clinically feasible treatment of depressive symptoms in 
this population is the use of a single, brief CT intervention focused on reducing negative 
thinking using thought-stopping and affirmations. Therefore, the purpose of this study 
was to test the short -term efficacy of a brief CT intervention aimed at decreasing 
negative thinking for the treatment of depressive symptoms in hospitalized patients with 
HF. We hypothesized that patients who received the brief CT intervention focused on 
reducing negative thinking would report lower levels of depressive symptoms and 
negative thinking, and better HRQOL and cardiac event-free survival at one week and 
three months compared to a usual care group.  
  
2. Methods 
2.1 Design  
 A randomized, controlled, repeated measures design was used to determine the 
short-term efficacy of a brief CT intervention. We followed the CONSORT (Consolidated 
Standards of Reporting Trials) guidelines.18
 A sample size of 21 patients per group was determined by an a priori power 
analysis estimate for a two-group univariate repeated measures ANOVA algorithm with 
Greenhouse-Geisser correction.
 The University of Kentucky Institutional 
Review Board and the Institutional Review Boards at participating hospitals approved 
the trial. All patients provided informed consent. Enrollment began February 2009 and 
ended December 2009; follow-up was completed in March 2010. 
19 A large effect size was chosen based on data from a 
prior study in which a large group difference in the short-term effect of a similar brief 
intervention was reported.20
2.2 Sample 
  With 21 subjects per group and an alpha level of .05, the 
power of the ANOVA F tests would be at least 95% to detect a main effect for group, a 
main effect for time, and the group by time interaction  
 Patients age 21 and older who were hospitalized with a primary or secondary 
diagnosis of HF at Central Baptist Hospital or Saint Joseph Hospital in Lexington, KY, 
were screened for study eligibility. Patients were candidates for inclusion if they had a 
confirmed diagnosis of preserved or non-preserved systolic function HF. We excluded 
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patients with co-existing terminal illness, end-stage HF (defined as mechanical pump 
support, continuous at home inotropic infusions, referral for heart transplant, or hospice 
care), cognitive impairment, and self-reported severe depression or suicidal ideation.  
Eligible patients were approached by the principal investigator (PI) on the second 
day of hospitalization or later. Recruitment was delayed if the patient was experiencing 
hypotension (blood pressure <80 mm Hg), a pain level of ≥ 5 on the 0-10 pain scale, or 
admission to an intensive care unit until medically stable. Patients who agreed to be in 
the study and provided written consent were screened for depressive symptoms with the 
Beck Depression Inventory version II (BDI). Those patients with mild to moderate 
symptoms of depression (BDI score 10-28) were enrolled in the trial. Participation for 
patients with no depressive symptoms or severe depressive symptoms ended after the 
baseline assessment; patients with severe depressive symptoms were referred to the 
attending physician for treatment. Two items on the BDI related to low energy and 
fatigue were not included in the upper cut-off score because patients admitted to the 
hospital with HF often report or experience HF-related fatigue. 
2.3 Randomization 
 A random allocation sequence was compiled using a true random number 
generator.21, 22
2.4 Procedure 
 Group assignments were placed in sealed, numbered envelopes. The 
investigators were blinded to the random allocation sequence. The PI enrolled the 
patient, completed the baseline assessment, and calculated the baseline BDI score. 
Immediately after completion of the baseline assessment, the PI opened the envelope to 
determine group assignment. Patients and investigators were not blinded to group 
assignment.  
Patients were approached by the PI, who introduced herself and explained the 
purpose of the visit. After written informed consent was obtained, the baseline data 
collection took place at the patient’s bedside. A chart review was conducted to obtain 
clinical and sociodemographic variables. Privacy was maintained throughout data 
collection by allowing patients to determine which family members or significant others 
they would like to have in the hospital room during study procedures.  
Both groups completed baseline questionnaires to measure depressive 
symptoms, negative thinking, and HRQOL. The PI read the questionnaires out loud for 
patients who needed assistance due to vision impairment, fatigue, or difficulty reading. 
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The PI calculated the BDI score and patients with mild to moderate depressive 
symptoms were randomized. Patients with severe depressive symptoms were 
encouraged to talk to their healthcare provider about their depressive symptoms, and the 
staff nurse, charge nurse, attending physician, and primary care physician were 
informed of the patient’s high level of depressive symptoms. Patients in the intervention 
group received the individual intervention prior to discharge, at a time convenient to the 
patient. Patients in the control group received usual care. 
One week after discharge, patients received a phone call reminder to complete 
and mail the one-week questionnaires. Patients who needed assistance were given the 
option of having the questionnaires read out loud over the phone. At three months, 
patients completed the questionnaires again by phone or mail, and patients were asked 
about current antidepressant medication use, hospitalizations, and emergency 
department visits that occurred since the baseline assessment. Patients were 
reimbursed $20 for the baseline assessment and $10 for each follow-up assessment.  
2.5 Intervention 
The intervention consisted of a single, brief, one-on-one CT session that took 
place in the hospital and a short telephone booster that took place one week post 
discharge. The brief CT session and booster were delivered by the PI, a Master’s-
prepared cardiovascular nurse, in collaboration with a PhD-prepared psychiatric clinical 
nurse specialist, who had tested a similar intervention with women at risk for depression 
in several randomized, controlled trials.16, 17 Previous qualitative work guided the design 
of the intervention.23
The script of the intervention followed six simple steps focused on reducing 
negative thinking using thought-stopping and affirmations (see Table 1). Patients were 
allowed to choose whether or not they would like a family member or significant other to 
be present during the intervention, which lasted approximately 30 minutes.  
 A colorful, 13 page flip chart with photos was used to guide the 
written script of the intervention. Patients also received a color booklet to take home.  
The booster CT session took place during the one week post discharge phone 
call (after the one week questionnaires were filled out) and lasted 5-10 minutes. During 
the booster, the PI talked with patients about negative thoughts they have been 
experiencing and asked about their experiences with the technique of thought-stopping 
followed by affirmation. The PI reinforced the technique and reminded patients of the 
importance of using thought-stopping and affirmations.  
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2.6 Usual care 
Patients in the control group received usual care, which consisted of standard 
evidence-based care for HF according to the American Heart Association/American 
College of Cardiology 2005 guidelines24 and the Joint Commission of Healthcare 
Organizations.25
2.7 Outcome measures 
 All patients with HF received individual discharge teaching on HF care, 
which included brief written instructions on the emotional consequences of living with 
HF. All patients were also offered the assistance of a chaplain if desired. In addition, 
patients in the control group received approximately 40-60 minutes of attention from the 
PI during recruitment, enrollment, and the baseline assessment. 
2.7.1 Depressive symptoms 
The primary outcome was depressive symptoms, which was defined as self-
reported symptoms that may exist with or without the presence of major depression.26 
The Beck Depression Inventory version II (BDI was used to measure depressive 
symptoms at baseline, one week post-discharge, and three months. The BDI contains 
21 items. Scores range from 0-63, with a score of 0-13 indicating none to minimal 
depressive symptoms, 14 to 28 indicating mild to moderate symptoms, and 29-63 
indicating severe symptoms.27 The BDI has well-established validity, reliability, and 
internal consistency for measurement of depressive symptoms in medical and non-
medical populations.28, 29
2.7.2 Health-related quality of life  
  
 Health-related quality of life (HRQOL) was defined as a patient’s perception of 
how HF has impacted the following domains of daily life: physical functioning, emotional 
status, health perception, and symptom burden. The Minnesota Living with HF 
Questionnaire (MLHFQ) was used to measure HRQOL. This instrument has been 
demonstrated to be reliable and valid in patients with HF.30
2.7.3. Negative thinking 
 Patients respond to 21-items 
with the stem question: “Did your HF prevent you from living as you wanted during the 
past month by.” The statements are rated from 0 (no impact) to 5 (most negative 
impact). Total scores range from 0 to 105. Higher scores indicate worse HRQOL.  
Negative thinking was defined as negative cognitions about the self, world, 
future, and withdrawal from others, and was measured using the Crandell Cognitions 
Inventory (CCI).9 The CCI is a 45-item scale that consists of 34 negative items and 11 
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positive, non-scored, buffer items. Patients are asked to endorse how frequently they 
experience a thought. Total scores are calculated by summing the item responses to the 
34 negative items; scores range from 34 to 170. Higher scores indicate a greater 
frequency of negative thinking. Researchers have demonstrated evidence for the 
reliability and validity of the CCI in psychiatric patients and healthy controls.
2.7.4. Event-free survival 
9 
A secondary endpoint was three-month cardiac event-free survival, defined as 
time to a combined end point of cardiovascular mortality, cardiovascular hospitalization, 
or cardiovascular emergency department (ED) visit. Dates and reasons for death, 
cardiovascular hospitalizations and ED visits were determined by medical record review 
and patient interview. A cardiovascular rehospitalization or ED visit was defined as an 
unanticipated admission for the following reasons: HF exacerbation, shortness of breath, 
cardiovascular-related chest pain, myocardial infarction, syncope, dysrhythmias 
(including internal cardiac defibrillator [ICD] firing), ICD or biventricular pacemaker 
placement due to worsening HF, coronary artery disease, hypertension, and palpitations.  
2.7.5. Additional variables of interest 
To completely describe the sample and obtain data on potential confounding 
variables, the following demographic information was collected at baseline: age, sex, 
race/ethnicity, marital status, education level, and months since diagnosis. The following 
clinical characteristics were determined by chart review: height, weight, smoking status, 
most recent left ventricular ejection fraction, comorbidities, and medications on 
discharge (i.e. drugs, doses, frequencies)..  
New York Heart Association (NYHA) functional class and comorbidities were also 
collected to further characterize the sample. NYHA functional class is a subjective 
indicator of functional status and was determined by patient interview at baseline and 
three months. Patients were assigned a classification of I (ordinary physical activity 
causes no symptoms of fatigue, dyspnea, angina or palpitations), II (symptoms with 
ordinary physical activity), III (symptoms occur with less than ordinary physical activity) 
or IV (symptoms occur even at rest).
2.8 Data analysis 
31 
Demographic and clinical differences between the groups were assessed using t-
tests or chi-square tests of association. Data analysis for each of the specific aims was 
conducted using intent-to-treat. To determine the effects of the intervention, repeated 
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measures ANOVA was used to compare levels of depressive symptoms, HRQOL, and 
negative thinking at baseline, one week post-discharge and three months between the 
two groups. The main effects for group, time, and group by time interaction were tested. 
Cardiac event-free survival was calculated using Kaplan-Meier survival curves with the 
log-rank test. Differences in the mean number of cardiac events between groups were 
determined with an independent t-test. An alpha of .05 was considered statistically 
significant for all analyses.  
3. Results 
3.1 Sample characteristics 
 A participant flow diagram is provided in Figure 6.1. Of the 407 patients who 
were screened for eligibility, 327 were excluded. The most common reasons for 
exclusion were cognitive impairment (n = 95), co-existing terminal illness (n = 34), and 
end-stage heart failure (n = 17).  
Eighty patients provided informed consent and were screened for depressive 
symptoms. Of these 80 patients, 42 (53%) had mild-moderate depressive symptoms and 
were retained in the study, while 33 patients (41%) with no depressive symptoms and 5 
patients (6%) with severe depressive symptoms were excluded. The characteristics of 
the final sample are provided in Table 6.2. The sample consisted of 42 patients with HF 
(45% female, 66 ± 11 years, 75% NYHA Class III). The mean depressive symptom 
score was 16.7 ± 6.7, which indicates mild depressive symptoms. One-third of the 
patients had a history of depression noted in the chart, and 41% were taking 
antidepressants at discharge. 
  There were no differences between intervention and control groups with regard 
to sex, age, NYHA Class, ejection fraction, marital status, ejection fraction, medications, 
and baseline depressive symptoms, negative thinking, or HRQOL. Patients in the control 
group had a higher mean body mass index, and patients in the intervention group were 
more likely to have prior coronary bypass graft surgery and co morbid chronic pulmonary 
obstructive disease. There were no baseline differences between groups with regard to 
depressive symptoms, HRQOL, and negative thinking.  
 Of the 41 patients for whom cardiac event-free survival data were collected, 19 
patients (54%) experienced a cardiovascular event during the three month follow-up 
period. Two patients died from worsening HF, 13 patients had at least one 
cardiovascular hospitalization, and 4 patients visited the ED for cardiovascular reasons.  
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3.2 Primary outcome 
 As shown in Table 6.3, BDI scores improved over time in both groups (p < .001); 
however, there were no significant difference between groups. Figure 6.2 suggests a 
trend for patients in the intervention group to have a faster improvement in depressive 
symptoms compared to patients in the control group, but this trend was not significant.  
3.3 Secondary outcomes 
 Table 6.3 also presents the data on HRQOL and negative thinking. Both groups 
experienced significant improvements in HRQOL and negative thinking over time. There 
were no significant group by time interactions for HRQOL or negative thinking. Although 
Figure 6.3 and 6.4 appear to show trends toward faster improvement in HRQOL and 
negative thinking in the intervention group compared to the control group, these trends 
were not significant. 
Patients in the intervention group had longer cardiac event-free survival 
compared to the control group (Figure 6.5). At three months, 80% of patients in the 
intervention group were alive without a cardiac event, compared to 40% of patients in 
the control group (p = .048). Furthermore, the mean number of cardiovascular events 
over the three month time period was higher in the control group compared to the 
intervention group (0.8 vs 0.2, p < .008).  
4. Discussion 
Researchers have established that depressive symptoms contribute to poor 
health outcomes in patients with HF.3 In this study, I tested the effects of a brief, clinically 
feasible CT intervention that can be administered by nurses for the treatment of 
depressive symptoms in hospitalized patients with HF. Patients in both groups 
experienced a significant improvement in depressive symptoms after discharge, but 
there were no differences between groups over time. It is likely that this was due to the 
large natural improvement that occurs with depressive symptoms after hospitalization for 
HF and attrition. Although the study was powered to detect differences in depressive 
symptoms between groups, I did not expect patients in both groups to experience such a 
large reduction in depressive symptoms during the follow-up period. In addition, data on 
depressive symptoms were missing from five patients in the control group (2 patients 
died, 2 patients declined further participation, and 1 was lost to follow-up) and 2 patients 
in the intervention group (1 was lost to follow-up, 1 was too busy to complete the 3 
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month questionnaires). Overall, the promising results of this pilot study support 
replicating the study with a larger sample size. 
We found that, in general, depressive symptoms improve soon after discharge in 
patients who are hospitalized with HF. Few researchers have described the trajectory of 
depressive symptoms in patients with HF. Koenig et al.32
Our finding that patients experience improvement in HRQOL after discharge is 
consistent with findings from Riegel et al.,
 found that although many 
patients with HF and depression experience spontaneous remission within several 
months after hospital discharge, 36% and 52% of patients continue to have symptoms of 
mild and major depression, respectively. The main predictor of shorter time to remission 
was lower levels of depressive symptoms. In our study, we enrolled patients with mild to 
moderate symptoms and excluded those with high levels of depressive symptoms. The 
mean level of depressive symptoms in our study was 16.. This relatively low level of 
depressive symptoms could explain why both groups improved rapidly after discharge. 
Future research is needed to determine whether brief CT interventions are beneficial in 
patients with higher levels depressive symptoms who are less likely to improve on their 
own. 
33
We also found that the intervention group had the same improvement in HRQOL 
as the usual care group. This result may be explained by findings from Riegel et al.,
 who combined data sets from nine 
experimental and quasi-experimental trials to determine the trajectory of HRQOL after 
hospitalization in patients who receive usual care. The investigators found that HRQOL, 
as measured by the Minnesota Living with Heart Failure Questionnaire, naturally 
improves by a mean of 13 points in the three months after hospital discharge. , 
33
 This is the first study to examine changes in negative thinking as a result of a CT 
intervention in patients with HF. Although there was a trend toward faster improvement 
in the intervention group and an increase in negative thinking in the control group after 
discharge, there were no significant differences between groups. Previous researchers 
have found that in women, negative thinking can be modified as a result of a similar CT 
intervention that uses thought-stopping and affirmations.
 
who found that only high-intensity interventions had an effect on HRQOL after 
hospitalization. Similarly, a more intense dose of the CT intervention offered in this study 
may be needed to improve HRQOL after discharge.  
16, 17 It is probable that we were 
unable to detect a difference between groups because of a small sample size and 
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missing data on the CCI. During the follow-up time points, several patients were too ill to 
complete all of the instruments, and in those cases the CCI was dropped from the 
questionnaire administration because of its length. A reliable and valid shortened version 
of the CCI would make it more practical for use in patients with an acute or chronic 
physical health condition. 
This study is the first to demonstrate that a brief, nurse-delivered CT intervention 
has a measurable impact on cardiac event-free survival in patients with HF. It is not clear 
why the intervention group experienced longer cardiac event-free survival when there 
were no differences between groups on depressive symptoms, negative thinking, or 
health-related quality of life. It is possible that patients in the intervention group 
experienced improvements in an unmeasured construct such as positive thinking or 
sympathetic nervous system activation.  
Furthermore, we do not know why a survival benefit was demonstrated in our 
small study when other investigators did not find a survival difference when testing CT in 
a much larger sample. The ENRICHD35
4.1 Limitations 
 investigators tested the effects of CT on survival 
in 2,481 patients with cardiovascular disease who had recently experienced a 
myocardial infarction and were diagnosed with clinical depression or self-reported poor 
social support. Although patients in the intervention group experienced a significant 
reduction in depressive symptoms as compared to the control group, there were no 
differences in cardiac event-free survival between groups. Our study differs from the 
ENRICHD study with regard to both patient population and timing of the cardiac 
outcome. Whereas the ENRICHD investigators recruited patients who had recently 
experienced a myocardial infarction, we enrolled patients who were experiencing an 
acute exacerbation of HF and were highly vulnerable to cardiac events during the three 
months post-hospitalization. In our study, we had an overall cardiac event rate of 54%, 
which may have contributed to our ability to detect a difference in outcomes. 
Furthermore, the ENRICHD investigators followed patients for an average of 29 months, 
while we measured cardiac event-free survival for three months. Future research is 
needed to test the effects of the brief CT intervention on long-term cardiac event-free 
survival in patients with HF.  
 Several limitations should be noted. First, this study needs to be replicated using 
a larger sample before definitive conclusions can be drawn. Second, due to resource 
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limitations, the follow-up questionnaires were administered by the same researcher (PI) 
who also administered the intervention. However, several steps were taken to reduce 
the potential for social desirability or researcher bias. The baseline assessment was 
completed prior to randomization so that the PI was blinded to group assignment during 
the first assessment. In addition, follow-up questionnaires were administered by mail 
whenever possible, and the PI did not discuss the intervention with the patient during the 
one-week and three-month assessment.  
5. Conclusions 
Our findings indicate that although depressive symptoms improve rapidly after 
discharge, patients would benefit from a nurse-administered, brief CT intervention while 
hospitalized for HF. This intervention is replicable, practical for the acute care setting, 
and may improve short-term cardiac event-free survival in patients with HF. Future 
research is needed to replicate this study using a randomized controlled trial that is 
powered to detect differences in primary and secondary outcomes, includes patients 
with higher levels of depressive symptoms, and incorporates a longer follow-up period.  
Copyright © Rebecca L. Dekker 2010  
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Table 6.1 Summary of the six steps of the brief cognitive therapy intervention 
Step 1: Depression and heart failure 
Description of symptoms of depression  
Depression is common in people with heart failure 
Bad news: Depression is bad for the heart 
Good news: There are treatments for depression 
Discussion question: “Do any of these symptoms of depression sound familiar to 
you?”  
Step 2: Thoughts, feelings, and behaviors 
The connection between thoughts, feelings and behaviors 
Thoughts can be false and negative, and these thoughts contribute to painful 
feelings and negative behaviors of depression 
Two real-life patient stories are told that demonstrate the link between a stressful 
situation and negative thinking, feelings, and behaviors 
Discussion question: “Do these stories sound familiar to you? Do you see how the 
person’s negative thinking led to painful feelings and negative behaviors?” 
Step 3: Your story 
Interactive component: Patient is asked to describe a recent stressful situation 
Discussion questions: “What kind of thoughts were going through your head? How 
did these thoughts make you feel? Did you notice any behaviors?”  
Step 4: Thought-stopping 
Notice you have a negative thought 
Snap your fingers or clap your hands and say, “Stop!” 
By stopping the negative thought you help take away the painful feelings that go 
with the thought 
Interactive component: Patient practices the stop technique with the interventionist 
Step 5: Affirmations 
An affirmation is a short, simple phrase that states how life is at its very best 
Use first person, present tense, and positive words; if you have a religious faith you 
may use it in your affirmation 
Interactive component: The patient comes up with 3-4 affirmations with the help of 
the interventionist 
The interventionist writes the affirmations on 2 brightly colored sticky notes: one for 
the hospital room and one for the patient to take home 
Step 6: Homework 
Practice the stop technique every time you hear a negative thought 
Hang the list of affirmations somewhere you will see it every day 
For every negative thought, think at least 2 positive thoughts 
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Table 6.2: Baseline characteristics of entire sample and patients randomly 
assigned to the brief cognitive therapy intervention versus usual care* 
Characteristic Overall 
sample  
(n = 42) 
Intervention 
group 
(n = 21) 
Usual care 
group 
(n = 21) 
p 
value 
Female 19 (45%) 10 (48%) 9 (43%) 0.8 
Age 66 ± 11 68 ± 10 64 ± 12 0.2 
Married  24 (57%) 14 (67%) 10 (48%) 0.2 
Minority 4 (10%) 2 (10%) 2 (10%) 1.0 
Education level     
      Less than high school 15 (36%) 10 (48%) 5 (25%) 0.3 
      High school graduate 12 (29%) 6 (30%) 6 (30%  
      Some college or 
greater 
14 (33%) 5 (24%) 9 (45%)  
Employment status     
      Employed  3 (7%) 2 (10%) 1 (5%) 0.5 
     Sick leave or disability 15 (36%) 9 (43%) 6 (30%)  
      Retired 21 (50%) 10 (48%) 13 (65%)  
Body Mass Index 31± 8.6 28.2 ± 6.4 33.8 ± 9.7 0.03 
NYHA functional class     
      Class II 8 (19%) 6 (29%) 2 (10%) 0.08 
      Class III 31 (74%) 15 (71%) 16 (76%)  
      Class IV 3 (7%) 0 (0%) 3 (14%)  
Left ventricular ejection 
fraction 
39.5± 16.4 40.8 ± 17 38.1 ± 16.1 0.6 
Etiology of HF     
Ischemic  26 (62%) 13 (62%) 13 (62%) 0.5 
Hypertensive 8 (19%) 4 (19%) 4 (19%)  
Idiopathic 6 (14%) 2 (10%) 4 (19%)  
Other 2 (10%) 2 (10%) 0 (0%)  
Smoking status     
Never smoked 17 (41%) 7 (33%) 10 (50%) 0.4 
Former smoker 14 (33%) 9 (43%) 8 (40%)  
Current smoker 7 (17%) 5 (24%) 2 (10%)  
Second hand smoke 
exposure 
12 (29%) 6 (29%) 6 (29%) 0.6 
Months since diagnosed 
with HF 
39 ± 56 45 ± 68 32 ± 37  
Newly diagnosed with HF 
in the past month 
13 (31%) 8 (38%) 5 (24%) 0.3 
History of depression  14 (33%) 9 (43%) 5 (24%) 0.2 
History of anxiety 13 (31%) 8 (38%) 5 (24%) 0.3 
Comorbidities     
Prior myocardial 
infarction 
17 (41%) 8 (38%) 9 (43%) 0.8 
Atrial fibrillation 19 (45%) 8 (38%) 11 (52%) 0.4 
CABG surgery 12 (29%) 10 (48%) 2 (9.5%) .006 
Biventricular 17 (41%) 8 (38%) 9 (43%) 0.8 
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pacemaker 
Implanted cardiac 
defibrillator 
19 (45%) 8 (38%) 11 (52%) 0.4 
Prior stroke 8 (19%) 4 (19%) 4 (19%) 1.0 
Chronic obstructive 
pulmonary disease 
17 (41%) 12 (57%) 5 (25%) 0.04 
Diabetes 19 (45%) 9 (43%) 10 (48%) 0.8 
Renal dysfunction 16 (38%) 9 (43%)  7 (33%) 0.5 
Medications on discharge     
ACE inhibitor 19 (45%) 10 (48%) 13 (62%) 0.4 
Antiogensin receptor 
blocker 
6 (14%) 3 (14%) 3 (14%) 1.0 
Beta blocker 36 (86%) 17 (81%) 19 (91%) 0.4 
Digoxin 17 (41%) 9 (43%) 8 (38%) 0.8 
Diuretic 26 (62%) 16 (76%) 10 (48%) .06 
Antidepressant 17 (41%) 8 (38%) 9 (43%) 0.8 
Laboratory values on 
admission 
    
B-type natriuretic 
peptide 
746 ± 914 963 ± 1171 529 ± 496 0.2 
BUN 26.2 ± 18.9 31.7 ± 23.6 20.5 ± 9.8 0.06 
Creatinine 1.3 ± 1.2 1.5 ± 1.6 1.1 ± 0.43 0.3 
Sodium 138.5 ± 6.2 138 ± 5.3 139 ± 7.2 0.7 
Beck Depression 
Inventory-II 
16.7 ± 6.7 15.8 ± 6.5 17.6 ± 6.7 0.4 
Minnesota Living with 
Heart Failure 
Questionnaire 
54 ± 25 50 ± 25 58± 25 0.3 
Crandell Cognitions 
Inventory 
61 ± 19 59 ± 19 64 ± 18 0.5 
*Data are given as n (%) or mean ± standard deviation unless otherwise indicated.  
Independent t-test used to test difference between 2 groups. Chi-square analysis was 
used for categorical variables.  
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Table 6.3 Primary and secondary outcomes in patients with heart failure 
 
CT = Cognitive Therapy, BDI-II = Beck Depression Inventory version II, CCI = Crandell Cognitions Inventory, MLHFQ = Minnesota 
Living with Heart Failure Questionnaire 
 
 
 Least-Squares Mean 
(SE) 
Time Group x Time 
Measure Brief CT 
Intervention 
Usual 
care 
 
F test p value Partial 
eta 
squared 
F test p value Partial eta 
squared 
BDI-II (n = 34) 
Baseline 
1 week 
3 months 
14.8 (5.5) 
9.9 (6.8) 
9.3 (5.4) 
17.5 (7.3) 
14 (9.6) 
10.7 (8.8) 
 
16.7 
 
< .001 
 
0.52 
 
.1.0 
 
.38 
 
0.06 
CCI (n = 32) 
Baseline 
1 week 
3 months 
61 (20) 
56 (23) 
54 (23) 
64 (20) 
68 (25) 
59 (22) 
 
3.3 
 
.05 
 
0.19 
 
0.8 
 
.47 
 
0.05 
MLHFQ (n = 32) 
Baseline 
1 week 
3 months 
51 (23) 
42 (25) 
29 (25) 
67 (18) 
64 (19) 
42 (25) 
 
13.7 
 
<.001 
 
0.49 
 
0.5 
 
.59 
 
0.04 
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Figure 6.1 Study flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n = 407) 
Excluded (n = 327) 
Did not meet criteria (n = 175) 
Declined to participate (n = 20) 
Discharged (n = 104) 
Other reasons (n = 28) 
Patients with mild-moderate 
symptoms who were 
randomized (n = 42) 
Allocated to usual care (n = 21) 
Allocated to intervention (n = 21) 
Received intervention (n = 20) 
Withdrawn; cognitive impairment 
discovered immediately after 
randomization (n = 1) 
Lost to follow up (n = 1)  
-Unable to contact 
Did not complete 3rd assessment 
(n = 1)  
-Too busy; during multiple phone 
calls stated “not a good time” 
 
Unable to contact (n = 1) 
-Phone disconnected 
Death prior to 3rd assessment (n = 2) 
Declined to complete follow-up 
assessments (n = 2) 
-“Too much work to talk about it” 
-Hung up on investigator several times 
without speaking 
 
Analyzed  
Depressive symptoms (n = 18) 
Negative thinking (n = 17) 
Health-related quality of life (n = 17) 
Cardiac event-free survival (n = 20) 
Excluded from analysis (n = 1) 
-Cognitive impairment; did not meet 
inclusion criteria 
Analyzed  
Depressive symptoms (n = 16) 
Negative thinking (n = 15) 
Health-related quality of life (n = 15) 
Cardiac event-free survival (n = 21) 
 
Consent obtained and patient screened for 
depressive symptoms (n = 80) 
No depressive symptoms (n = 33) 
Mild-moderate symptoms (n = 42) 
Severe depressive symptoms (n = 5) 
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Figure 6.2 Change in depressive symptoms over time (n = 34) 
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Figure 6.3 Changes in health-related quality of life over time (n = 32) 
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Figure 6.4 Changes in negative thinking over time (n = 32) 
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Figure 6.3 Kaplan-meier cardiac event-free survival curve (n = 41; log rank test p < 
.05). 
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CHAPTER SEVEN: 
Conclusions 
1. Background and purpose  
The overall purpose of this dissertation was to develop and test a brief CT 
intervention for the treatment of depressive symptoms in patients with HF. The following 
manuscripts were completed prior to testing the CT intervention: 1) a review of the 
evidence for CT in treating depressive symptoms in patients with cardiovascular-related 
conditions,1 2) a qualitative study to describe the experience of living with depressive 
symptoms in patients with HF and identify strategies that could be used to manage these 
symptoms,2 3) a critical review of the literature to identify a measure of negative thinking 
that can be used in patients with HF3
The presence of depressive symptoms is an important clinical problem in 
patients with HF. One out of five patients with HF suffers from major depressive 
disorder, and an even higher percentage of patients experience self-reported depressive 
symptoms.4 Experiencing even mild symptoms of depression place a patient with HF at 
higher risk for mortality, morbidity, and worse health-related quality of life.4, 5  
, and 4) an evaluation of the psychometric 
properties of this measure of negative thinking. Based on findings from these 
manuscripts, a randomized, controlled pilot study was conducted to test the effects of a 
brief CT intervention on outcomes of hospitalized patients with HF who report depressive 
symptoms. 
Depressive symptoms are under-diagnosed and under-treated in patients with 
HF. Up to 40% of patients with HF who have depression are not recognized as 
depressed by health care providers.6 The treatment of depression in this population is 
complicated by a lack of specific guideline recommendations for depressive symptoms in 
patients with HF.7 Although researchers have described the problem of depression in 
patients with HF, little is known about which treatments may be effective. Recent 
evidence suggests that nursing interventions may be more effective than 
antidepressants for the treatment of clinical depression in patients with HF.8 Cognitive 
therapy (CT) is an intervention that can be administered by nurses9 and may be an 
effective treatment for depressive symptoms in patients with HF.  
The purpose of this chapter is to summarize and synthesize the findings of this 
dissertation. This chapter will also advance the state of the science of the treatment of 
depressive symptoms in patients with heart failure (HF) by making recommendations for 
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practice and future research.  
2. Summary of findings 
Chapter Two is a review of the literature1 on the current evidence for CT 
interventions in patients with cardiovascular-related illnesses. Based on limitations of the 
studies and mixed results, it was concluded that there is insufficient evidence to 
recommend the use of CT for the treatment of depressive symptoms in patients with 
cardiovascular conditions. It was recommended that future researchers test CT 
interventions in patients with HF via large, randomized, controlled trials that incorporate 
the following design elements: the CONSORT guidelines for reporting of clinical trials, 
adequate representation of women, long-term follow up (at least one year), and 
replicable descriptions of the CT intervention. It was also concluded that research is 
needed to determine whether CT is effective for patients with HF who have an acute 
exacerbation, the appropriate dose of a CT intervention, and the impact of the 
intervention on other outcomes, such as health-related quality of life and cardiovascular 
events.  
Chapter Three is a qualitative study2 in which patients with HF described the 
experience of living with depressive symptoms. This study was nested in a randomized, 
controlled trial testing biofeedback and CT in outpatients with HF. The patients described 
experiencing negative thoughts such as “I can’t justify my existence,” “I have nothing to 
offer anymore,” and “I’m a failure.” The patients stated that “dwelling” on these negative 
thoughts worsened their depressed mood. The patients also described using positive 
thinking to manage their depressive symptoms, thus providing support for a CT 
intervention in this population. The use of a cognitive strategy was an expected finding in 
the five participants who received biofeedback and CT in the larger study. However, the 
control group participants, who never received a CT intervention, also discussed positive 
thinking as a strategy for managing depressive symptoms. This finding suggests that 
interventions focused on reducing negative thinking using thought-stopping and 
affirmations may be particularly welcomed by patients with HF. However, negative 
thinking has never been quantitatively measured in patients with HF. 
Chapter Four is a critical review of the literature3 to identify a measure of 
negative thinking that has the best potential for use in patients with HF. Three of the 
most widely used instruments for measuring negative thinking were reviewed: the 
Crandell Cognitions Inventory, Automatic Thoughts Questionnaire, and Cognitive 
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Checklist- Depression. The Crandell Cognitions Inventory (CCI) was recommended as 
having the highest potential for measuring negative thinking in patients with HF. The CCI 
has the advantage of being developed with a clinical population and captures a wide 
range of negative thinking content. However, the CCI required psychometric testing 
among patients with HF before it can be recommended for use.  
  Chapter Five is an evaluation of the reliability and validity of the CCI in patients 
with HF. Cross-sectional questionnaire data were collected from 179 outpatients with 
HF. Cronbach’s alpha was 0.96, indicating adequate internal consistency but probable 
redundancy. Corrected item-total correlations were greater than 0.4, indicating adequate 
homogeneity. Negative thinking displayed a dose-response relationship with depressive 
symptoms. The CCI had a stronger correlation with depressive symptoms than anxiety. 
Overall, the results support the reliability and validity of the CCI as a measure of 
negative thinking in patients with HF, although a shortened version would be more 
practical for use in the clinical setting.  
 Chapter Six is the RCT testing the brief CT intervention in hospitalized patients 
with HF. Forty-two patients with HF who reported mild-moderate depressive symptoms 
were randomized to a single, brief CT intervention focused on reducing negative 
thoughts with thought-stopping and affirmations, or to usual care control. Although there 
were trends toward faster improvement in depressive symptoms, HRQOL and negative 
thinking in the intervention group, these trends were not significant. While both groups 
improved in all three variables over time, the intervention group experienced longer 
cardiac event-free survival and fewer cardiovascular events compared to the control 
group. Combined, the results suggest that it is beneficial to administer a brief CT 
intervention in the acute care setting to patients with HF who experience mild-moderate 
symptoms of depression. 
3. Impact of dissertation on the state of the science 
There is little evidence supporting non-pharmacological interventions for the 
treatment of depressive symptoms in patients with HF. Although researchers and 
clinicians had established that depressive symptoms are a significant clinical problem in 
patients with HF, no interventions had been shown to improve the negative sequelae 
associated with depressive symptoms. The state of the science in treating depressive 
symptoms is such that the latest American College of Cardiology and American Heart 
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Association guidelines7 did not include specific recommendations for screening or 
treatment of depressive symptoms in patients with HF.  
 I have advanced the state of the science in the treatment of depressive 
symptoms in patients with HF by: 1) identifying components that are necessary for the 
design of clinical trials that test CT interventions for depressive symptoms in patients 
with HF, 2) describing negative thinking as an important target for the treatment of 
depressive symptoms in patients with HF, 3) developing a brief CT intervention based on 
evidence from the qualitative study, 4) identifying a measure of negative thinking and 
providing evidence for its reliability and validity in patients with HF, 5) showing that it is 
both practical and beneficial to provide a CT intervention to patients with HF who are 
hospitalized, 6) and demonstrating that a nurse-delivered, brief CT intervention improves 
cardiac event-free survival in patients with HF.  
First, Chapter Two1 identified important design components that are needed in 
future clinical trials testing CT treatments for depressive symptoms in patients with HF. 
Subsequently, the RCT presented in Chapter Six incorporated these recommendations. 
The RCT included recommended design components such as: intentional sampling of 
50% females, a scripted, replicable intervention, measurement of HRQOL and cardiac 
event-free survival, and following the CONSORT guidelines for reporting the results of 
the trial.  
Next, in the qualitative study in Chapter Three,2 I identified negative thinking as a 
key modifiable target for depressive symptoms in patients with HF. This finding is 
consistent with Beck’s cognitive model of depression which posits that negative thinking 
influences the emotional, behavioral, and somatic symptoms of depression.10 For 
patients in the qualitative study, the most commonly used strategy for managing 
depressive symptoms was the use of positive thinking. Positive thinking for these 
patients was defined as the redirection of thoughts away from the negative (i.e., thought-
stopping) and focusing instead on affirmations, such as “I’m alive” and “My mind and 
soul are strong and healthy.” 
Based on the findings from Chapter Three, a brief CT intervention was developed 
for use in hospitalized patients with HF who have depressive symptoms. Strategies 
discussed by patients comprised four of the six steps of the brief, 30 minute intervention 
(Table 1) presented in Chapter Six. These strategies included: understanding the 
relationship between stressful situations, negative thinking, and symptoms of 
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depression; personal stories told by the patients about how negative thoughts influenced 
their feelings and behaviors; thought-stopping or refusing to “dwell” on negative 
thoughts; and the use of written and verbal affirmations. A colorful, 13 page flip chart 
with photos was developed to guide the script of the intervention, and color booklet 
versions were printed for patients to take home. Although a similar CT intervention using 
thought-stopping and affirmations has previously been tested in women at risk for 
depression,11, 12 this intervention has never been tested in patients with HF. The 
intervention tested in this dissertation was particularly innovative because of its brevity 
(30 minutes), practicality, and potential to be implemented by nurses in the acute care 
setting.  
To determine the effectiveness of CT to reduce negative thinking as a treatment 
for depressive symptoms in patients with HF, researchers need a valid and reliable 
measure of negative thinking in this population. In Chapters Four3 and Five, I advanced 
the state of the science in depression and heart failure by identifying an instrument with 
the best potential for measuring negative thinking and providing strong evidence for its 
reliability and validity in patients with HF. It is recommended that the CCI be used to 
measure changes in negative thinking in studies testing CT interventions in patients with 
HF. However, the CCI may need to be shortened and undergo further psychometric 
testing to make it more practical for the clinical setting. 
In the review of the literature presented in Chapter Two,1 I determined that we do 
not know whether it is practical or beneficial to offer a CT intervention to patients with HF 
who are hospitalized. For example, the ENRICHD investigators13 found that a CT 
intervention did not improve survival outcomes in patients with HF who had recently 
experienced an acute myocardial infarction. These investigators questioned whether it 
was appropriate to administer an intervention after an acute cardiac event. The findings 
from our study in Chapter Six suggest otherwise—we found that it is both practical and 
beneficial to deliver a brief CT intervention to hospitalized patients with HF.  
Finally, this dissertation represents an important contribution to the literature 
because it was the first study to show that a nurse-delivered, non-pharmacological 
intervention for depressive symptoms in patients with HF is associated with longer 
cardiac event-free survival and fewer cardiovascular events compared to usual care.  
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4. Recommendations for nursing practice and research 
Depressive symptoms are an important predictor of mortality and morbidity in 
patients with HF that require intervention. Results from the recent SADHART-HF study8 
suggest that nursing interventions may be more effective than antidepressant therapy for 
the treatment of depressive symptoms in patients with HF. If future clinical trials provide 
additional evidence that antidepressant therapy has limited benefit for patients with HF, 
non-pharmacological interventions could emerge as a preferred method of treatment for 
depressive symptoms in patients with HF. This however, will also require additional 
evidence to demonstrate the effectiveness of non-pharmacological interventions for 
depressive symptoms in patients with HF. 
The CT intervention tested in this dissertation was designed to be brief (30 
minutes) because of the time constraints of nurses working in the acute care setting.  
It is recommended that acute care nurses use this brief intervention to improve 
outcomes of patients with HF who report depressive symptoms.  
Additional studies are planned to expand upon this pilot study. My next step will 
be evaluate the psychometric properties of a shortened version of the CCI using data 
collected from outpatients (N = 179) and inpatients with HF (N = 80) who enrolled in the 
studies described in Chapters Five and Six. After shortening the CCI, I plan to conduct a 
large, randomized controlled trial to test the long-term effects of the brief CT intervention 
provided to patients who are hospitalized with HF. This study will be adequately powered 
to detect differences in all primary and secondary outcomes. Furthermore, the study will 
include patients with higher levels of depressive symptoms and incorporate a follow-up 
period of at least one year.  
Depressive symptoms have important clinical consequences in patients with HF, 
and nursing interventions may be an important treatment strategy of the future. This 
dissertation has fulfilled an important gap in the evidence base for depression treatment 
in patients with HF by demonstrating that a nurse-delivered, brief CT intervention may 
improve cardiac event-free survival in patients with HF. This brief CT intervention is 
replicable, practical, and can be delivered by acute care nurses to improve clinical 
outcomes in patients with HF.  
Copyright © Rebecca L. Dekker 2010 
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Table 7.1: Summary of the six steps of the brief cognitive therapy intervention 
Step 1: Depression and heart failure 
Description of symptoms of depression  
Depression is common in people with heart failure 
Bad news: Depression is bad for the heart 
Good news: There are treatments for depression 
Discussion question: “Do any of these symptoms of depression sound familiar to 
you?”  
Step 2: Thoughts, feelings, and behaviors 
The connection between thoughts, feelings and behaviors 
Thoughts can be false and negative, and these thoughts contribute to painful 
feelings and negative behaviors of depression 
Two real-life patient stories are told that demonstrate the link between a stressful 
situation and negative thinking, feelings, and behaviors 
Discussion question: “Do these stories sound familiar to you? Do you see how the 
person’s negative thinking led to painful feelings and negative behaviors?” 
Step 3: Your story 
Interactive component: Patient is asked to describe a recent stressful situation 
Discussion questions: “What kind of thoughts were going through your head? How 
did these thoughts make you feel? Did you notice any behaviors?”  
Step 4: Thought-stopping 
Notice you have a negative thought 
Snap your fingers or clap your hands and say, “Stop!” 
By stopping the negative thought you help take away the painful feelings that go with 
the thought 
Interactive component: Patient practices the stop technique with the interventionist 
Step 5: Affirmations 
An affirmation is a short, simple phrase that states how life is at its very best 
Use first person, present tense, and positive words; if you have a religious faith you 
may use it in your affirmation 
Interactive component: The patient comes up with 3-4 affirmations with the help of 
the interventionist 
The interventionist writes the affirmations on 2 brightly colored sticky notes: one for 
the hospital room and one for the patient to take home 
Step 6: Homework 
Practice the stop technique every time you hear a negative thought 
Hang the list of affirmations somewhere you will see it every day 
For every negative thought, think at least 2 positive thoughts 
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